

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
23 October 2003 (23.10.2003)

PCT

(10) International Publication Number  
**WO 03/087165 A2**

(51) International Patent Classification<sup>7</sup>: **C08B 37/00**,  
C08H 1/00, C08B 31/12, 11/06, 11/12, 11/193, 13/00,  
C08H 1/06, C08G 65/48, C08F 8/18, 216/06, C08G 73/02,  
A61K 49/06, 49/12, 49/14, 49/16

(21) International Application Number: PCT/US03/11039

(22) International Filing Date: 11 April 2003 (11.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/372,500 11 April 2002 (11.04.2002) US

(71) Applicant (for all designated States except US): **CAR-  
BOMER** [US/US]; 6324 Ferris Square, San Diego, CA  
92121 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **VALPANI, Manssur**  
[US/US]; 17136 Blue Skies Ridge, Rancho Santa Fe, CA  
92127 (US).

(74) Agents: **SALIWANCHIK, David, R.** et al.; Saliwanchik,  
Lloyd & Saliwanchik, Suite A-1, 2421 N.W. 41st Street,  
Gainesville, FL 32606-6669 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,  
SE, SG, SK, SI, TJ, TM, TN, TR, TT, TZ, UA, UG, US,  
UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished  
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: **BIOCOMPATIBLE MATERIALS AND PROBES**



(57) Abstract: The present invention relates to fluorinated biopolymer and polymer derivatives useful as imaging probes, diagnostic agents and contrast agents and to imaging methods employing the fluorinated biopolymers and polymers.

BEST AVAILABLE COPY

WO 03/087165 A2

## DESCRIPTION

### BIOCOMPATIBLE MATERIALS AND PROBES

#### Cross-Reference to a Related Application

This application claims the benefit of provisional patent application Serial No. 60/372,500, filed April 11, 2002, which is hereby incorporated by reference in its entirety.

#### Field of the Invention

The present invention relates to fluorinated biopolymer and polymer derivatives useful as imaging probes, diagnostic agents and contrast agents and to imaging methods employing the fluorinated biopolymers and polymers.

#### Background

Hyaluronic acid (or hyaluronan, HA) is a high molecular weight copolymer of 1→3-β-linked *N*-acetyl-D-glucosamine-1→4-β-D-glucuronic acid from the glycosaminoglycans family of biopolymers with unusual rheological properties. Its physiological functions include the lubrication and protection of cells, maintenance of tissue structural integrity, and transport of molecules to and within cells. HA is found in the extracellular matrix (ECM) and plays an integral role in its organization and structure. Hyaluronan influences cellular proliferation and migration in developing, regenerating and remodeling tissues and in tissues undergoing malignant tumor-cell invasion (see, e.g., B.P. Toole S.D. Banerjee, *Oligosaccharides reactive with hyaluronan-binding protein*, monoclonal antibodies recognizing hyaluronan-binding protein, and use in cancer therapy, U.S. Patent 5,902,795, 1999; S. Kumar, D. West, D.B. Rifkin, M. Klagsburn (eds.) *Hyaluronic acid and its degradation products modulate angiogenesis in vivo and in vitro*. In *Current Communications in Molecular Biology; Angiogenesis: Mechanism and Pathobiology*, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, pp. 90-94, 1987.).

HA binds specifically to proteins in the ECM, within the cytosol and on cell-surface receptors. The prevalence of hyaluronan-binding proteins indicates the importance of HA recognition in tissue organization, proliferation and differentiation, growth factor activities, and the control of cellular adhesion and motility. HA's role extends to embryonic development, modulation of inflammation, stimulation of angiogenesis and wound healing, and morphogenesis.

A number of extracellular matrix and cellular proteins, the hyaladherins, have specific affinities to HA within the extracellular matrix. These include aggrecan, cartilage link-protein, hyaluronectin, neurocan and versican. Cellular hyaluronan receptors such as CD44 (CD = "cluster of differentiation") and RHAMM (receptor for hyaluronate-mediated motility) are also known. Recent evidence implicates the CD44-HA interaction in cancer metastasis (for reviews, see Entwistle, J.; Hall, C. L.; Turley, E. A. *J. Cell. Biochem.*, **61**, 569-577, 1996;

Bajorath, J. *Proteins: Struct. Funct. Genet.*, **39**, 103–111, 2000.). Melanoma cells expressing high CD44 levels show increased cell motility and metastatic potential compared to the same cell types that expressed low receptor levels (see e.g., Birch, M.; Mitchell, S.; Hart, I. *Cancer Res.*, **51**, 6660–6667, 1991.). The presence of specific HA cell receptors provides therefore potential uses in cancer diagnosis and therapy. Other biomedical uses include cataract surgery, osteoarthritis, and prevention of post-surgical adhesions. HA also displays useful wetting and moisture-preserving functions that are of interest in cosmetic and topical medical areas. HA sources include rooster combs, umbilical cords, shark skin, bull's eye and fermentation.

The integrin receptor family binds to ECM receptors (S.M. Abelda, Role of integrins and other cell adhesion molecules in tumor progression and metastasis, *Lab Invest.*, **68**, 4-17, 1993.). Integrins are heterodimeric glycoproteins with two subunits ( $\alpha$  and  $\beta$ ). A given  $\beta$ -subunit can pair with a number of  $\alpha$ -subunits, resulting in various integrins with unique binding properties. Thus,  $\alpha 2 \beta 1$  constitutes a collagen receptor that does not interact with laminin on platelets (C.J. Anderson, *Bioconjugate Chem.* **12**, 1057-65, 2001.)

Normal human tissue cells express various integrins such as  $\alpha 1 \beta 1$ ,  $\alpha 2 \beta 1$ ,  $\alpha 3 \beta 1$ , and  $\alpha 6 \beta 1$  that are required for adhesion to collagen and laminin (J. L. Lauer, C. M. Gendron, G. B. Fields, Effect of ligand conformation on melanoma cell alpha3beta1 integrin mediated signal translocation event Implication for a collagen structural modulation mechanism of tumor cell invasion, *Biochemistry*, **37**, 5279-87, 1998.). Radiolabeled ECM fragments are useful imaging agents since their integrins are upregulated in certain tumors and can be targeted for diagnosis and therapy. Integrins promote adhesion, signal transduction and linkage between intracellular proteins and ligands. ECM fragments are used as imaging agents as their integrins are upregulated in certain tumor types and can be targeted for diagnostic or therapeutic use.

The ubiquitous nature of HA in biological systems, coupled with its antitumor and diverse range of other medical activities make diagnostic probe-carrying HA derivatives attractive for diagnostic and therapeutic uses. There is furthermore growing evidence that oligosaccharides derived from hyaluronan also bind to CD44. Thus, if an antagonist could be found for the CD44 receptor that would prevent HA binding, it would be possible consequently to limit metastasis. Such small molecules would have advantages over HA itself in that they would possibly be water soluble, membrane penetrating, and easy to administrate. Minimally, a 6-mer (hexasaccharide) is required for binding to CD44 and the 10-mer (decasaccharide) is required to displace HA from the HA-CD44 complex.

Other acidic polysaccharides, such as alginate and pectin are possibly also biologically active, as some evidence indicates in the literature (A. Kawada, N. Hiura, S. Tajima, H. Takahara, Alginate oligosaccharides stimulate VEGF-mediated growth and migration of human endothelial cells, *Arch. Dermatol. Res.*, **291**, 542-7, 1999; M. Sakurai, H.T. Matsumoto, H. Kiyohara, H. Yamada, B-cell proliferation activity of pectic

polysaccharides from a medicinal herb, *Immunology*, 97, 540-7, 1999; H. Yamada, Contribution of pectins on health care, in J. Visser, A.G.J. Voragen eds., *Pectins and Pectinases*, Elsevier, Amsterdam, 173-190, 1996; H. Yamada, H. Kiyohara, Complement-activating polysaccharides from medicinal herbs, in H. Wagner ed., *Immunomodulatory Agents from Plants*, Birkhauser Verlag, Basel, 1999.). The preparation of alginate oligosaccharides (A. Martinsen, G. Skjak-Braek, O. Smidsrod, *Carbohydr. Polym.*, 15, 171-173, 1991. Ikeda, H-F, A.A Takemura, H Ono, *Carbohydr. Polym.*, 42, 421-425, 2000.) and pectic oligosaccharides (N.O. Maness, A.J. Mort, *Anal. Biochem.*, 178, 248-254, 1989.) has been reported.

Hyaluronan has attracted considerable interest as biocompatible, resorbable material for tissue engineering and a wide range of other biomedical applications (for reviews, see D. Campoccia, P. Doherty, M. Radice, P. Brun, G. Abatangelo, D.F. Williams, Semisynthetic resorbable materials from hyaluronan esterification, *Biomaterials*, 19, 2101-2127, 1998; E. Milella, E. Brescia, C. Massaro, P.A. Ramires, M.R. Miglietta, V. Fiori, P. Aversa, Physico-chemical properties and degradability of non-woven hyaluronan benzylic esters as tissue engineering scaffolds, *Biomaterials*, 23, 1053-1063, 2002.) A considerable number of hyaluronan derivatives have been reported (see, e.g., K. P. Vercruysee, G. D. Prestwich, Hyaluronate derivatives in drug delivery, *Crit. Rev. Therapeut. Carrier Syst.*, 15, 514-555, 1998; Y. Luo, G. D. Prestwich, Hyaluronic acid-N-hydroxysuccinimide: a useful intermediate for bioconjugation, *Bioconjugate Chem.* 12, 1085-88, 2001.). Collagen, the other major component of the extracellular matrix, constitutes over 30% of the human protein content and is associated with a number of diseases. Collagen has therefore been similarly widely employed as biocompatible matrix, as have hybrid materials derived from collagen and hyaluronan (S.-N. Park, J.-C. Park, H. O. Kim, M. J. Song, H. Suh, Characterization of porous collagen/hyaluronic acid scaffold modified by 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide cross-linking, *Biomaterials*, 23, 1205-1212, 2002). Collagen features an unusual amino acid composition: glycine constitutes over 30%, proline and hydroxyproline about 20%, whilst it lacks tryptophan and cysteine (i.e., no disulfide bonds).

Poly(glutamic acids), and in particular poly( $\gamma$ -glutamic acid) ( $\gamma$ -PGA) are new biodegradable materials with many potential biomedical uses (I.-L. Shih, Y.-T. Van, The production of poly( $\gamma$ -glutamic acid) from microorganisms and its various applications, *Bioresource Techn.*, 79, 207-225, 2001).  $\gamma$ -PGA, elaborated by various *Bacillus* species (e.g., *B. licheniformis*), is an unusual polypeptide with its glutamic acid residues linked linearly through the  $\gamma$ -carboxyl function.  $\gamma$ -PGA assumes an  $\alpha$ -helix conformation in solution, and, unlike the synthetic  $\alpha$ -PGA analog, is a well-defined, high molecular weight homopolymer.

$\gamma$ -PGA's polyanionic nature renders it highly water soluble and permits modulation of its solution conformation by co-solutes. PGAs ability to undergo conformational changes in response to different pH values offers the potential to affect targeted delivery.  $\gamma$ -PGA features a high molecular weight range and different solution conformations, is biocompatible,

biodegradable (it biodegrades to glutamic acid monomers), non-toxic, and non-immunogenic nature.  $\gamma$ -PGA is also highly mucoadhesive, a key feature for localizing it site-specifically as a drug delivery vehicle in the small intestinal or colonic mucosa.

Radiolabeled peptide hormone analogues are of interest as diagnostic and therapeutic vehicles for treating cancer (Cutler C.S. Lewis J. S. Anderson C.J. *Adv. Drug Deliv. Res.*, **37**, 189-211, 1999. Anderson C.J. Welch M.J., *Chem. Rev.*, **99**, 2219-2234, 1999.; Anderson C.J. Dehdashti F Cutler P.D. Schwarz S W. Laforet R. Bass L. R. Lewis J..S. McCarthy D. W., *J. Nucl. Med.*, **42**, 213-2334, 2001.). These radiolabeled peptide receptor ligands can target upregulated cell surface receptors on tumors. For example,  $^{111}\text{In}$ -DTPA-octreotide is employed for imaging of neuroendocrine tumors that overexpress the somastatin receptor (E.P. Krenning, D. J. Kwekboom, W. H. Bakker, W. A. P. Breeman, P. P. M. Kooji, H. Y. Oei, M. van Hagen, P. T. E. Postema, M. de Jong, J. C. Reubi, T.J. Visser, A. E. M. Reji, L. L. J. Holland, J. W. Kuuper, S. W. J. Lamberts, Somatostatin receptor scintigraphy with [ $^{111}\text{In}$ -DTPA-D-Phe] and [ $^{111}\text{In}$ -Tyr<sup>3</sup>]octreotide, *Eur. J. Nucl. Med.*, **20**, 716-731, 1993.).

Primary human tumors from colon, ovary, skin and stomach and their metastatic sites show high levels of  $\alpha\beta 1$ , and similarly cultured human cell lines (e.g., breast, ovarian carcinoma) express  $\alpha\beta 1$ . Non-invasive means of monitoring  $\alpha\beta 1$  expression could be useful as a diagnostic tool for assessing metastasis prior to surgery. Since natural collagens are integrin ligands radiolabeled collagen fragments can serve as imaging agents.

There is a considerable demand for versatile non-invasive diagnostic probes, and fluorine's diagnostic value is of particular interest in non-invasive imaging applications. Apolar oxygen imparts paramagnetic relaxation effects on  $^{19}\text{F}$  nuclei associated with spin-lattice relaxation rates ( $R_1$ ) and chemical shifts. This effect is proportional to the partial pressure of  $\text{O}_2$  ( $p\text{O}_2$ ).  $^{19}\text{F}$  NMR can therefore probe the oxygen environment of specific fluorinated species in cells and other biological structures.

Nöth et al. (U. Nöth, P. Grohn, A. Jork, U. Zimmermann, A. Haase, J. Lutz,  $^{19}\text{F}$ -MRI in vivo determination of the partial oxygen pressure in perfluorocarbon-loaded alginate capsules implanted into the peritoneal cavity and different tissues, *Magn. Reson. Med.*, **42**(6), 1039-47, 1999) employed perfluorocarbon-loaded alginate capsules in MRI experiments to assess the viability and metabolic activity of the encapsulated materials. Quantitative  $^{19}\text{F}$ -MRI was performed on perfluorocarbon-loaded alginate capsules implanted into rats, in order to determine *in vivo* the  $p\text{O}_2$  inside the capsules at these implantation sites. Fraker et al. reported recently a related method with perfluorotributylamine (C. Fraker, L. Invaeradi, M. Mares-Guia, C. Ricordi, PCT WO 00/40252, 2000).

Although a large range of fluorinated products is available commercially, most PFCs suffer from a number of shortcomings. Many commercial PFCs currently employed for diagnostic purposes were originally selected for blood substitution. Their physicochemical properties [J. G. Reiss et al., *Biomat. Artif. Cells Artif. Organs*, **16**, 421-430, 1988.] are therefore not targeted towards specific diagnostic or other biomedical uses, particularly for

MRI. The molecular features of these PFCs are not optimized for high-sensitivity  $^{19}\text{F}$ -MRI studies. Their  $T_1$  relaxation times are relatively long,  $T_2$  relaxation times are short, and severe J-modulation effects and chemical shift artifacts can profoundly limit their MRI utility. Whilst their immiscibility in water offers benefits in some respects, it necessitates the use of emulsifiers. Thus, for PFC-in-water emulsions, such as F-44E, perfluorohexyl bromide (PFHB), perfluorooctyl bromide (PFOB, Perflubron<sup>TM</sup>), perfluoromethyldecalin (PMD), perfluorooctyl ethane (PFOE), perfluorotripropylamine (FTPA), and the blood substitutes Fluosol<sup>TM</sup> and Oxygent<sup>TM</sup>, lecithins or poloxamers are employed to disperse the PFCs and stabilize the emulsion. Fluosol<sup>TM</sup> was a 20% w/v mixture of 14% perfluorodecalin and 6% perfluorotripropylamine emulsified primarily with Pluronic F-68<sup>TM</sup>. Oxygent<sup>TM</sup> is a 60% emulsion consisting mostly of PFOB and perfluoro-decylbromide, water, salts, and a lecithin. However, surfactants are problematic in that their use adds processing requirements and some of them can be unstable, chemically ill-defined or polydisperse, or cause potential undesirable side effects. Thus, Pluronic F-68<sup>TM</sup>, the surfactant in Fluosol<sup>TM</sup>, caused a transitory anaphylactic reaction in certain patients. Further, the stability of Pluronic F-68-based emulsions was limited; requiring frozen storage and mixing with two annex solutions prior to administration. The use of emulsions poses the additional disadvantage that the PFCs' fluorine content is effectively diluted (often by 50% or more), diminishing their spectral and imaging signal intensities and, hence diagnostic benefit. The impact of such dilutions is particularly evident in tumor oxygenation studies where only ~10% of the injected PFC emulsion dose reaches the tumor, necessitating time consuming  $T_1$  measurements. This dilution effect is even more pronounced, when only a portion of the available PFCs' fluorine resonances is of diagnostic value. This is often the case, as severe chemical shift artifacts need to be circumvented by selectively exciting only a narrow chemical shift range containing one resonance (or a closely spaced group of resonances). Although F-44E, for instance, has a high fluorine content (74%) with largely acceptable spectral features, many MRI studies have selectively excited its trifluoromethyl resonance, representing only one third of the total F-content, which on emulsification (at 90%) is further diluted to ~22%. Similarly, for MRI with perfluorononane the choice is between the selective acquisition of the single trifluoromethyl resonance (6 fluorines with a spectral width of 50 kHz at 7 Tesla) or multiple difluoromethylene resonances (14 fluorines with a 1300 kHz spectral dispersion) (see, e.g., S.L. Fossheim; KA Il'yasov, J. Hennig, A. Bjornerud, *Acad. Radiol.*, 7(12), 1107-15, 2000.).

Ideally, PFC imaging agents should combine the following features: non-toxic, biocompatible, chemically pure and stable, low vapor pressure, high fluorine content, reasonable cost and commercial availability. Additionally, they should meet several  $^{19}\text{F}$ -NMR criteria, including a maximum number of chemically equivalent fluorines resonating at one or only few frequencies, preferably from trifluoromethyl functions. Some of the other spectral criteria have been discussed in detail elsewhere (C. H. Sotak, P. S. Hees, H. N. Huang, M. H. Hung, C. G. Krespan, S. Raynolds, *Magn. Reson. Med.*, 29, 188-195, 1993.). For MRI, it

would furthermore be desirable to have control over the amount of magnetically responsive material for specific uses, and to employ temperature-responsive and pH-dependent imaging agents for special uses. These could have applications in MRI-based temperature monitoring for use in general hyperthermia treatment (see, e.g., S. L. Fossheim; K. A. Il'yasov, J. Hennig, A. Bjornerud, *Acad. Radiol.*, **7**(12), 1107-15, 2000.) of tumors and for monitoring the efficacy of chemotherapy, respectively (see, e.g., N. Rhagunand, R. Martinez-Zagulan, S. H. Wright, R. J. Gilles, *Biochem. Pharmacol.*, **57**, 1047-1058, 1999; I. F Tannock, D. Rotin, *Cancer Res.*, **49**, 4373-4383, 1989.). Furthermore, water solubility would enhance the PFC functionality in many biomedical settings, as it would obviate the need for emulsifiers.

Although selected efforts have been directed at developing new fluorinated MRI probes, none are water soluble compounds [e.g., perfluoro-[15]-crown-5 ether)], and some are commercially unavailable [e.g., perfluoro-2,2,2',2'-tetramethyl-4,4'-bis(1,3-dioxalane)-PTBD]. It appears no attempts have so far focused on screening available PFCs from the thousands of commercial fluorinated products in order to identify potentially more suitable MRI probes for biomedical uses. It seems furthermore that no studies have attempted to establish structure activity relations (SARs) of related PFCs for MRI purposes. Noteworthy is also the fact that all PFCs examined to date have molecular weights under 1,000, typically between 400-600 Da. This is partly a reflection of the specific requirements for blood substitution agents, but also due to the widely held belief that higher molecular weight or polymeric fluorinated agents would not be detectable by  $^{19}\text{F}$ -NMR due to anticipated excessive line broadening, and would therefore be unsuitable. Thus, with the exception of the polymer-encapsulated PFCs noted above, this important class of materials had so far been excluded from consideration.

Paramagnetic ions, such as gadolinium ( $\text{Gd}^{3+}$ ) decrease the  $T_1$  of water protons in their vicinity, thereby providing enhanced contrast. Gadolinium's long electron relaxation time and high magnetic moment make it a highly efficient  $T_1$  perturbant. Since uncomplexed gadolinium is very toxic, gadolinium chelate probes, such as gadolinium diethylenetriamine pentaacetic acid ( $\text{GdDTPA}$   $M_w$  570 Da), albumin- $\text{GdDTPA}$  (Gadomer-17,  $M_w$  35 or 65 kDa), have been employed extensively in MRI of tumors and other diseased organs and tissues. Several other developmental chelators have also been reported, including dual-labeled agents, oligonucleotide-derived, dextran-derived  $\text{GdDTPA}$ , and TAT and other peptide-derived chelators. However, presently approved MRI contrast agents are either not tissue specific, e.g.,  $\text{GdDTPA}$ , or target only normal tissue, which limits their utility in diagnosis of metastases or neoplasia. MRI studies with  $\text{GdDTPA}$ , for instance, do not correlate with the angiogenic factor or the vascular endothelial growth factor (VEGF). Attempts have also been made to overcome the low relaxivities of small  $\text{Gd-DTPA}$  chelates by preparing polymer conjugates of  $\text{Gd(DTPA)}^{(2-)}$  [see e.g., M. R. A. Duarte, M.G. Gil, M.H. Peters, J. A. Colet, J. M. Elst, L. Vander; R.N. Muller, C. F. G. C. Geraldes, *Bioconjug. Chem.*, **21**, 170-177, 2001.]. However, the relaxivity of these polymer conjugates was only slightly improved and they were

also cleared very quickly from the blood of rats, indicating that they are of limited value as blood pool contrast agents for MRI.

Whilst much can be achieved with currently available imaging and contrast agents, there are still unmet needs for novel diagnostic agents, particularly for those exploiting biological specificity. Imaging agents suitable for targeting metastases or neoplasia would substantially enhance the MRI sensitivity and utility for tumor detection and prevention. Although selected efforts have been directed at developing such new probes, a broader investigation of these agents is urgently needed. Similarly, new imaging probes are needed as noninvasive means to detect and image cells, tissues and organs undergoing apoptosis. An even greater demand exists for biocompatible materials in tissue engineering and various other biomedical applications.

#### Brief Description of the Drawing


Figure 1 shows a NMR spectrum of the perfluoroalkyl hyaluronan of Example 2.

#### Summary of the Invention

The present invention relates to fluorinated biopolymer and polymer derivatives (Formulas I-XX) useful as imaging probes, diagnostic agents and contrast agents. Additionally, the present invention relates to imaging methods employing the present compounds of Formulas I-XX

Novel compositions comprising modified biopolymers of the present invention include the compounds of general formula I to VIII and their use as new biomaterials, imaging probes, diagnostic tools and contrast agents:






I


II

III




IV

V



VI

VII



VIII

Where

For Formula I:

5  $R_1 = H, X; R_2 = H, X; R_3 = H, OH, OY, OX, NHX$

For Formula II:

$R_1 = H, X; R_2 = H, X; R_3 = H, OY, OX, NHX$

10 For Formula III:

$R_1 = H, X; R_2 = H, X; R_3 = H, Y, X$

For Formula IV:

15  $R_1 = H, X; R_2 = H, X; R_3 = CO_2H, CO_2X, CH_2X, CH_2NHX; R_4 = H, X; R_5 = H, X; R_6 = H, X; R_7 = X, COCH_3, COX$

For Formula V:

$R_1 = H, X$ ;  $R_2 = H, X$ ;  $R_3 = CO_2H, CO_2X, CH_2X, CH_2NHX$ ;  $R_4 = H, SO_3H, X$ ;  $R_5 = H, SO_3H, X$ ;  $R_6 = H, X$ ;  $R_7 = COCH_3, COX, X$

5 For Formula VI:

$R_1 = H, X$ ;  $R_2 = H, X$ ;  $R_3 = CO_2H, CO_2X, CH_2X, CH_2NHX$ ;  $R_4 = H, X$ ;  $R_5 = SO_3H, X$ ;  $R_6 = H, X$ ;  $R_7 = COCH_3, COX, X$

For Formula VII:

10  $R_1 = H, X$ ;  $R_2 = H, X$ ;  $R_3 = H, X$ ;  $R_4 = SO_3H, X$ ;  $R_5 = SO_3H, X$ ;  $R_6 = H, X$ ;  $R_7 = COCH_3, COX, X$

For Formula VIII:

15  $R_1 = H, X$ ;  $R_2 = H, X$ ;  $R_3 = CO_2H, CO_2X, CH_2X, CH_2NHX$ ;  $R_4 = H, X$ ;  $R_5 = H, X$ ;  $R_6 = H, X$ ;  $R_7 = H, X$ ;  $R_8 = COCH_3, COX, X$

Wherein for all of the above Formulas

X = fluoroalkyl, fluoroaryl, fluoroacyl, perfluoroalkyl, perfluoroaryl, perfluoroacyl, perfluoropolymer, fluoroamine, fluorocarbamate, fluorotriazine, fluorosulfonylalkyl derivatives,

20  $CF_2Cl$ ,  $SO_2[CF_2]_xCF_3$ , F,  $CF_3$ ,  $COC_xF_y$ ,  $C_xF_yH_z$ ,  $[(CH_2)_mO]_x(CH_2CF_2O)_y(CF_2CF_2O)_z(CF_2)_2CF_2CH_2O(CH_2)_pOH$ ,  $CH_2C(OH)C_xF_yH_z$ ,  $C_xF_yH_2O_p$ ,  $COC_xF_yH_z$ ,  $OCH_2C_xF_z[C_xF_zO]_mF$ ,  $CH_2C(CH_3)CO_2C_xH_z(CF_2)_mCF_3$ ,  $CH_2(CF_2O)_x(CF_2CF_2O)_y(CF_2O)_zCF_2CH_2OH$ ,  $COCF(CF_3)-[CF(CF_3)CF_2O]_mF$ ,  $NHC_xF_yH_2O_p$ ,  $CH_2CF_2O[CF_2CF_2O]_m(CF_2OCF_2CH_2OH)$ ,  $COC_xH_z(CF_2)_mCF_3$ ,


25  $COCF_2O[CF_2CF_2O]_nCF_2OCF_2CO_2H$ ,  $[(CH_2)_mO]_x(CH_2CF_2O)_y(CF_2CF_2O)_zCF_2CH_2O(CH_2)_pOH$ ,  $N[C_xF_yH_z]_p$ ,  $C_xH_zCO_2C_xH_z(CF_2)_mCF_3$ ,  $COC_xF_y[C_xF_zO]_mF$ , a luminescent residue, a fluorescent residue, a fluorinated luminescent residue or a fluorinated fluorescent residue and m, x, p, y, z are integers from 1 to 150, and where m is more preferably 10-100, and most preferably 10-50, and where x, p, y, z are more preferably 10-75, even more preferably 10-50, and most

30 preferably 10-20. Acyl and alkyl residues in the above formulas comprise lipophilic moieties, including saturated and unsaturated aliphatic residues with  $C_k$  chains, where k is 2 to 100, more preferably 2-50, and most preferably 2-20, and aryl residues comprise aromatic moieties, including benzyl, biphenyl, phenyl polycyclic aromatics, and heteroatom-containing aromatics; and


35 Y = saccharide branch residue comprised of mono-, di-, oligo- or polysaccharide, fluorinated saccharide branch residue comprised of mono-, di-, oligo- or polysaccharide.

The novel compositions are comprised of modified biopolymers, wherein said biopolymers include biopolymers that are selected from the group consisting of amylose, cellulose, dextran, dextrans, galactan,  $\beta$ -glucans, glycosaminoglycans, including chondroitin sulfate, dermatan sulfate, heparan sulfate, heparin, hyaluronate, and keratin sulfate, maltodextrins, mannans, pustulan, starch, xylans and their copolymers, linear or cyclic oligomers, hybrids, salts and derivatives.


Novel compositions comprising modified biopolymers of the present invention include the compounds of general formula IX to XII and are disclosed herein as new biomaterials, imaging probes, diagnostic tools and contrast agents:




IX



X



XI



XII

wherein

For Formula IX:

$R_1 = H, X, Z$ ;  $R_2 = H, X, Z$ ;  $R_3 = H, X$ ;  $R_4 = H, X, Z$ ;  $R_5 = H, X$ ;  $R_6 = H, X$ ;  $R_7 = H, X, Z$

For Formula X:

$R_1 = H, X, CH_2OGOCO_2H, CH_2OGCO_2X, CH_2OGCONX, CH_2OGCH_2NX$ ;  $R_2 = H, X, Z$ ;  $R_3 = H, X, CH_2OGOCO_2H, CH_2OGCO_2X, CH_2OGCONX, CH_2OGCH_2NX$ ;  $R_4 = H, COCH_3, COX, X, CH_2OGOCO_2H, CH_2OGCO_2X, CH_2OGCONX, CH_2OGCH_2NX$

For Formula XI:

$R_1 = H, OH, X, OX, OZ, CH_2OGOCO_2H, CH_2OGCO_2X, CH_2OGCONX, CH_2OGCH_2NX$ ;  $R_2 = H, OH, X, OX, OZ, CH_2OGOCO_2H, CH_2OGCO_2X, CH_2OGCONX, CH_2OGCH_2NX$ ;  $R_3 = CH_2OH, CH_2OX, CH_2OZ, CH_2X, CH_2NHX, CO_2H, CO_2X, CONX, CH_2OGOH, CH_2OGOX, CH_2OGOCO_2H, CH_2OGCO_2X, CH_2OGCONX, CH_2OGCH_2NX$ ;  $R_4 = OH, Z, OX, X$ ;  $G = \text{alkyl, hydroxyalkyl}$

For Formula XII:

K = H, OH, X, OX, OZ; L = H, OH, X, OX, OZ; W = H, OH, X, OX, OZ; T = H, OH, X, OX, OZ;  
V = anhydrofuranosyl, anhydropyranosyl, and m, n, p, q, r = 1-500 inclusive; n = 1-8 inclusive.

5

Wherein for all of the above Formulas


X = fluoroalkyl, fluoroaryl, fluoroacyl, perfluoroalkyl, perfluoroaryl, perfluoroacyl, perfluoropolymer, fluoroamine, fluorocarbamate, fluorotriazine, fluorosulfonylalkyl derivatives, F, CF<sub>2</sub>Cl, SO<sub>2</sub>[CF<sub>2</sub>]<sub>x</sub>CF<sub>3</sub>, CF<sub>3</sub>, COC<sub>x</sub>F<sub>y</sub>, C<sub>x</sub>F<sub>y</sub>H<sub>z</sub>,  
10 ([CH<sub>2</sub>]<sub>m</sub>O)<sub>x</sub>(CH<sub>2</sub>CF<sub>2</sub>O)<sub>y</sub>(CF<sub>2</sub>CF<sub>2</sub>O)<sub>z</sub>(CF<sub>2</sub>)<sub>2</sub>CF<sub>2</sub>CH<sub>2</sub>O(CH<sub>2</sub>)<sub>p</sub>OH, CH<sub>2</sub>C(OH)C<sub>x</sub>F<sub>y</sub>H<sub>z</sub>, C<sub>x</sub>F<sub>y</sub>H<sub>z</sub>O<sub>p</sub>, COC<sub>x</sub>F<sub>y</sub>H<sub>z</sub>, OCH<sub>2</sub>C<sub>x</sub>F<sub>z</sub>[C<sub>x</sub>F<sub>z</sub>O]<sub>m</sub>F, CH<sub>2</sub>C(CH<sub>3</sub>)CO<sub>2</sub>C<sub>x</sub>H<sub>z</sub>(CF<sub>2</sub>)<sub>m</sub>CF<sub>3</sub>, CH<sub>2</sub>(CF<sub>2</sub>O)<sub>x</sub>(CF<sub>2</sub>CF<sub>2</sub>O)<sub>y</sub>(CF<sub>2</sub>O)<sub>z</sub>CF<sub>2</sub>CH<sub>2</sub>OH, COCF(CF<sub>3</sub>)-[CF(CF<sub>3</sub>)CF<sub>2</sub>O]<sub>m</sub>F, NHC<sub>x</sub>F<sub>y</sub>H<sub>z</sub>O<sub>p</sub>, CH<sub>2</sub>CF<sub>2</sub>O[CF<sub>2</sub>CF<sub>2</sub>O]<sub>m</sub>(CF<sub>2</sub>OCF<sub>2</sub>CH<sub>2</sub>OH, COC<sub>x</sub>H<sub>z</sub>(CF<sub>2</sub>)<sub>m</sub>CF<sub>3</sub>, COCF<sub>2</sub>O[CF<sub>2</sub>CF<sub>2</sub>O]<sub>n</sub>CF<sub>2</sub>OCF<sub>2</sub>CO<sub>2</sub>H, ([CH<sub>2</sub>]<sub>m</sub>O)<sub>x</sub>(CH<sub>2</sub>CF<sub>2</sub>O)<sub>y</sub>(CF<sub>2</sub>CF<sub>2</sub>O)<sub>z</sub>CF<sub>2</sub>CH<sub>2</sub>O(CH<sub>2</sub>)<sub>p</sub>OH,  
15 N[C<sub>x</sub>F<sub>y</sub>H<sub>z</sub>]<sub>p</sub>, C<sub>x</sub>H<sub>z</sub>CO<sub>2</sub>C<sub>x</sub>H<sub>z</sub>(CF<sub>2</sub>)<sub>m</sub>CF<sub>3</sub>, COC<sub>x</sub>F<sub>y</sub>[C<sub>p</sub>F<sub>z</sub>O]<sub>m</sub>F, a luminescent residue, a fluorescent residue, a fluorinated luminescent residue or a fluorinated fluorescent residue and m, x, p, y, z are integers from 1 to 150, and where m is more preferably 10-100, and most preferably 10-50, and where x, p, y, z are more preferably 10-75, even more preferably 10-50, and most preferably 10-20. Acyl and alkyl residues in the above formulas comprise lipophilic moieties,  
20 including saturated and unsaturated aliphatic residues with C<sub>k</sub> chains, where k is 2 to 100, more preferably 2-50, and most preferably 2-20, and aryl residues comprise aromatic moieties, including benzyl, biphenyl, phenyl polycyclic aromatics, and heteroatom-containing aromatics.

Y = saccharide branch residue comprised of mono-, di-, oligo- or polysaccharide, fluorinated  
25 saccharide branch residue comprised of mono-, di-, oligo- or polysaccharide.

Z = acyl, alkyl

The present compositions are comprised of modified biopolymer that include biopolymers that are selected from the group consisting of linear, branched, cyclic, ionic or  
30 neutral glycans, such as acacia, agar, alginate, arabinogalactans, arabinoxylans, carageenans, cyclodextrins, fructooligosaccharides, fucoidan, gellan, galactomannans, glucomannans, inulins, pectin, pullulan, tragacanth, xanthan, and xyloglucans, carboxyalkyl glycans, such as carboxymethyl cellulose, carboxymethyl chitosan, and carboxymethyl dextran, glycan esters, such as cellulose acetate, cellulose phosphate, cellulose sulphate and starch acetate, aminoglycans, such as chitin, chitosan, emulsan, and poly(galactosamine),  
35 hydroxyalkyl glycans, such as hydroxyethyl cellulose, hydroxypropyl cellulose, alkylglycans such as ethylcellulose and methylcellulose, polysialic acid, and their oligomers, hybrids, salts and derivatives.

Novel compounds of this invention include compositions comprising modified biopolymers of general formula XIII as new biomaterials, imaging probes, diagnostic tools and contrast agents:



XIII

Where

For Formula XIII:

K = H, OH, X, OX, OZ, (Y)<sub>i</sub>; L = H, OH, X, OX, OZ, (Y)<sub>i</sub>; W = H, (CH<sub>2</sub>)<sub>d</sub>, CO<sub>2</sub>H, CH, CX, X; T = H, OH, X, OX, OZ; V = (CH<sub>2</sub>)<sub>d</sub>, CH<sub>2</sub>OX, CH<sub>2</sub>OZ, CH<sub>2</sub>X, CH<sub>2</sub>NHX; S = H, O, X, NHX, (Y)<sub>i</sub>; T = H, O, X, NHX, (Y)<sub>i</sub>; R<sub>1</sub> = H, X and d = 1-3; f, n = 1-1,500, preferably f, n = 100-1,000


Wherein

Wherein for all of the above Formulas


X = fluoroalkyl, fluoroaryl, fluoroacyl, perfluoroalkyl, perfluoroaryl, perfluoroacyl, perfluoropolymer, fluoroamine, fluorocarbamate, fluorotriazine, fluorosulfonylalkyl derivatives, F, CF<sub>3</sub>, CF<sub>2</sub>Cl, SO<sub>2</sub>[CF<sub>2</sub>]<sub>x</sub>CF<sub>3</sub>, COC<sub>x</sub>F<sub>y</sub>, C<sub>x</sub>F<sub>y</sub>H<sub>z</sub>, ([CH<sub>2</sub>)<sub>m</sub>O]<sub>x</sub>(CH<sub>2</sub>CF<sub>2</sub>O)<sub>y</sub>(CF<sub>2</sub>CF<sub>2</sub>O)<sub>z</sub>(CF<sub>2</sub>)<sub>2</sub>CF<sub>2</sub>CH<sub>2</sub>O(CH<sub>2</sub>)<sub>p</sub>OH, CH<sub>2</sub>C(OH)C<sub>x</sub>F<sub>y</sub>H<sub>z</sub>, C<sub>x</sub>F<sub>y</sub>H<sub>2</sub>O<sub>p</sub>, COC<sub>x</sub>F<sub>y</sub>H<sub>z</sub>, OCH<sub>2</sub>C<sub>x</sub>F<sub>z</sub>[C<sub>x</sub>F<sub>2</sub>O]<sub>m</sub>F, CH<sub>2</sub>C(CH<sub>3</sub>)CO<sub>2</sub>C<sub>x</sub>H<sub>z</sub>(CF<sub>2</sub>)<sub>m</sub>CF<sub>3</sub>, CH<sub>2</sub>(CF<sub>2</sub>O)<sub>x</sub>(CF<sub>2</sub>CF<sub>2</sub>O)<sub>y</sub>(CF<sub>2</sub>O)<sub>z</sub>CF<sub>2</sub>CH<sub>2</sub>OH, NHC<sub>x</sub>F<sub>y</sub>H<sub>2</sub>O<sub>p</sub>, CH<sub>2</sub>CF<sub>2</sub>O[CF<sub>2</sub>CF<sub>2</sub>O]<sub>m</sub>(CF<sub>2</sub>OCF<sub>2</sub>CH<sub>2</sub>OH, COC<sub>x</sub>H<sub>z</sub>(CF<sub>2</sub>)<sub>m</sub>CF<sub>3</sub>, CO- CF<sub>2</sub>O[CF<sub>2</sub>CF<sub>2</sub>O]<sub>n</sub>CF<sub>2</sub>OCF<sub>2</sub>CO<sub>2</sub>H, COCF(CF<sub>3</sub>)-[CF(CF<sub>3</sub>)CF<sub>2</sub>O]<sub>m</sub>F, ([CH<sub>2</sub>)<sub>m</sub>O]<sub>x</sub>(CH<sub>2</sub>CF<sub>2</sub>O)<sub>y</sub>(CF<sub>2</sub>CF<sub>2</sub>O)<sub>z</sub>CF<sub>2</sub>CH<sub>2</sub>O(CH<sub>2</sub>)<sub>p</sub>OH, N[C<sub>x</sub>F<sub>y</sub>H<sub>z</sub>]<sub>p</sub>, C<sub>x</sub>H<sub>z</sub>CO<sub>2</sub>C<sub>x</sub>H<sub>z</sub>(CF<sub>2</sub>)<sub>m</sub>CF<sub>3</sub>, COC<sub>x</sub>F<sub>y</sub>[C<sub>p</sub>F<sub>z</sub>O]<sub>m</sub>F, a luminescent residue, a fluorescent residue, a fluorinated luminescent residue or a fluorinated fluorescent residue and m, x, p, y, z are integers from 1 to 150, and where m is more preferably 10-100, and most preferably 10-50, and where x, p, y, z are more preferably 10-75, even more preferably 10-50, and most preferably 10-20. Acyl and alkyl residues in the above formulas comprise lipophilic moieties, including saturated and unsaturated aliphatic residues with C<sub>k</sub> chains, where k is 2 to 100, more preferably 2-50, and most preferably 2-20, and aryl residues comprise aromatic moieties, including benzyl, biphenyl, phenyl polycyclic aromatics, and heteroatom-containing aromatics. Y = amino acid residue, fluorinated amino acid residue. Z = acyl, alkyl.

The novel compositions are comprised of modified biopolymers that include biopolymers that are selected from the group consisting of collagens, elastins, gelatins, poly(amino acids), including poly(aspartic acid), poly(glutamic acid), and poly(lysine), biopolyesters, including poly(glycolic acid), poly(hydroxy alkanates), and poly(lactic acid), their copolymers, oligomers, hybrids, salts and derivatives.


Novel compositions of this invention also include compounds comprising modified polymers of general formula XIV to XX and their use as new biomaterials, imaging probes, diagnostic tools and contrast agents:




XIV




XV




XVI




XVII



XVIII



XIX



XX

Where

For Formula XIV:

R<sub>1</sub> = H, X; R<sub>2</sub> = H, Z, X.

For Formula XV:

R<sub>1</sub> = H, CH<sub>3</sub>, (CH<sub>2</sub>)<sub>m</sub>CH<sub>3</sub>, CF<sub>3</sub>, (CF<sub>2</sub>)<sub>m</sub>CF<sub>3</sub>; R<sub>2</sub> = H, CH<sub>3</sub>, (CH<sub>2</sub>)<sub>m</sub>CH<sub>3</sub>, CF<sub>3</sub>, (CF<sub>2</sub>)<sub>m</sub>CF<sub>3</sub>; R<sub>3</sub> = H, CH<sub>3</sub>, (CH<sub>2</sub>)<sub>m</sub>CH<sub>3</sub>, CF<sub>3</sub>, (CF<sub>2</sub>)<sub>m</sub>CF<sub>3</sub>; R<sub>4</sub> = H, CH<sub>3</sub>, (CH<sub>2</sub>)<sub>m</sub>CH<sub>3</sub>, CF<sub>3</sub>, (CF<sub>2</sub>)<sub>m</sub>CF<sub>3</sub>; R<sub>5</sub> = H, CH<sub>3</sub>, (CH<sub>2</sub>)<sub>m</sub>CH<sub>3</sub>, CF<sub>3</sub>, (CF<sub>2</sub>)<sub>m</sub>CF<sub>3</sub>, CH<sub>2</sub>X, CH<sub>2</sub>NHX; R<sub>6</sub> = H, CH<sub>3</sub>, (CH<sub>2</sub>)<sub>m</sub>CH<sub>3</sub>, CF<sub>3</sub>, (CF<sub>2</sub>)<sub>m</sub>CF<sub>3</sub>, CH<sub>2</sub>X, CH<sub>2</sub>NHX; m = 1-10; n = 1-3,000.

For Formula XVI:

R<sub>1</sub> = OH, X, OX, OZ; R<sub>2</sub> = OH, X, OX, OZ; m, n = 1-15,000, preferably m, n = 500-2,000.

For Formula XVI:

$R_1 = O, CH_2X, CH_2NHX, OZ$ ;  $R_2 = CH_3, (CH_2)_mCH_3$ ;  $R_3 = CH_3, (CH_2)_mCH_3, CF_3, (CF_2)_mCF_3$ ;  $R_4 = (CH_2)_n$ ;  $R_5 = (CH_2)_q$ ;  $R_6 = H, OH, OX, X$ ;  $R_7 = H, OH, OX, X$ ;  $m, n = 1-30$ ;  $p, q = 0-3,000$ ; preferably  $p, q = 50-500$ .

5 For Formula XVII:

$R_1 = O, OX, CF_3, (CF_2)_mCF_3$ ;  $R_2 = CH_3, (CH_2)_nCH_3, CF_3, (CF_2)_nCF_3$ ;  $R_3 = CH_3, (CH_2)_nCH_3, CF_3, (CF_2)_nCF_3$ ;  $R_4 = (CH_2)_m$ ;  $R_5 = (CH_2)_q$ ;  $R_6 = OH, OX, X$ ;  $R_7 = H, X$ ;  $m = 1-2$ ;  $n = 1-10$ ;  $p, q = 1-3,000$ , preferably  $p, q = 100-1,000$ .

10 For Formula XVIII:

$R_1 = H, CH_3, (CH_2)_mCH_3, CF_3, (CF_2)_mCF_3$ ;  $R_2 = H, OH, OX, X$ ;  $R_3 = H, OH, OX, X$ ;  $m = 1-30$ ;  $n = 1-3,000$ , preferably  $n = 500-1,000$ .

For Formula XIX:

15  $R_1 = CH_2, CH_2CH_2, CF_2, CF_2CF_2$ ;  $R_2 = CH_2, CF_2$ ;  $R_3 = OH, OX, OZ$ ;  $R_4 = H, X, Z$ ; where  $Z = Y[(OCH_2CH_2)_m]_q$ ;  $Y =$  multidentate core, such as trivalent or tetravalent residues;  $m, n = 1-80,000$ , preferably  $m, n = 1,000-20,000$ ;  $q = 1-10$ .

For Formula XX:

20  $R_1 = H, X$ ;  $R_2 = H, X, (CH_2CH_2N)_m, (CH_2CH_2NX)_m$ ;  $R_3 = H, X, (CH_2CH_2N)_m, (CH_2CH_2NX)_m$ ;  $R_4 = H, X, (CH_2CH_2N)_mCH_2CH_2NH_2, (CH_2CH_2N)_mCH_2CH_2NHX$ ;  $m = 1-3,000$ ;  $n = 5-80,000$ , preferably  $n = 500-15,000$ .

Wherein for all of the above Formulas

25  $X =$  fluoroalkyl, fluoroaryl, fluoroacyl, perfluoroalkyl, perfluoroaryl, perfluoroacyl, perfluoropolymer, fluoroamine, fluorocarbamate, fluorotriazine, fluorosulfonylalkyl derivatives,  $F, CF_3, COC_xF_y, C_xF_yH_z,$   
 $[(CH_2)_9O]_x(CH_2CF_2O)_y(CF_2CF_2O)_z(CF_2)_2CF_2CH_2O(CH_2)_pOH, CH_2C(OH)C_xF_yH_z, C_xF_yH_zO_p,$   
 $COC_xF_yH_z, OCH_2C_xF_z[C_xF_zO]_gF, CH_2C(CH_3)CO_2C_xH_z(CF_2)_gCF_3,$   
 30  $CH_2(CF_2O)_x(CF_2CF_2O)_y(CF_2O)_zCF_2CH_2OH, CF_2Cl, SO_2[CF_2]_xCF_3, NHC_xF_yH_zO_p,$   
 $CH_2CF_2O[CF_2CF_2O]_g(CF_2OCF_2CH_2OH, COC_xH_z(CF_2)_gCF_3, CO-$   
 $CF_2O[CF_2CF_2O]_nCF_2OCF_2CO_2H, CO-CF(CF_3)-[CF(CF_3)CF_2O]_gF$   
 $[(CH_2)_9O]_x(CH_2CF_2O)_y(CF_2CF_2O)_zCF_2CH_2O(CH_2)_pOH, N[C_xF_yH_z]_p,$   
 $C_xH_zCO_2C_xH_z(CF_2)_gCF_3, COC_xF_y[C_xF_zO]_mF,$  a luminescent residue, a fluorescent residue,  
 35 a fluorinated luminescent residue or a fluorinated fluorescent residue and  $g, x, p, y, z$  are integers from 1 to 150, and where  $g$  is more preferably 10-100, and most preferably 10-50, and where  $x, p, y, z$  are more preferably 10-75, even more preferably 10-50, and most preferably 10-20. Acyl and alkyl residues in the above formulas comprise lipophilic moieties, including saturated and unsaturated aliphatic residues with  $C_k$  chains, where  $k$

is 2 to 100, more preferably 2-50, and most preferably 2-20, and aryl residues comprise aromatic moieties, including benzyl, biphenyl, phenyl polycyclic aromatics, and heteroatom-containing aromatics.

Z = acyl, alkyl.

5

The novel compositions are comprised of modified polymers that include polymers that are selected from the group consisting of biocompatible polymers, including poly(acrylates), poly(acrylamides), poly(alkylene glycols), including poly(ethylene glycols), poly(ethylene oxides) and poly(propylene glycols), poly(allylamines), poly(butadienes),  
10 poly(caprolactones), poly(ethylene imines), poly(methacrylates), poly(orthoesters), poly(tetrahydrofurans), poly(vinyl pyrrolidones), poly(vinyl acetates), and poly(vinyl alcohols), their copolymers, oligomers, hybrids, salts and derivatives and where acyl and alkyl residues of this disclosure comprise lipophilic moieties, including saturated and unsaturated aliphatic residues with C<sub>k</sub> chains, where k is 2 to 100, more preferably 2-50, and most preferably 2-20,  
15 and where aryl residues comprise aromatic moieties, including benzyl, biphenyl, phenyl, polycyclic aromatics, and heteroatom-containing aromatics.

15

The fluorinated and/or paramagnetic polymers of the present invention are used to improve the imaging available in an MRI examination procedure. The method of improving the effectiveness of magnetic resonance imaging (MRI) comprises:

20

- a. administering an effective amount of one or more fluorinated and/or paramagnetic polymers of Claims 1-4 to a patient;
- b. subjecting the patient to an MRI of a tissue/organ where the administered polymer is expected to accumulate; and
- c. evaluating the tissue/organ from the MRI images obtained.

25

One of ordinary skill in the art would readily be able to evaluate the results of the MRI by observation and/or comparisons to a patient's prior MRI results or standard MRI results used for diagnosis purposes.

30

#### Detailed Description of the Invention

Compositions of this invention comprised of carbohydrate, polymer and protein residues are obtained by treating the respective starting materials (backbone or substrate moiety) with fluorine moieties employing routine fluorination chemistry such as those described below.

35

Three general approaches can be employed to prepare the new fluorinated biopolymers of the instant invention: (1) low molecular weight fluorinated substituents can be employed (as illustrated in the Examples); (2) high molecular weight polyfluorinated residues can be employed, such as with functional perfluoropolymers; and (3) fluorinated monomers can be incorporated into polymeric materials by chemical or enzymatic processes. The above



approaches permit the preparation of fluorinated biopolymers with a broad range of fluorine substituent types and incorporation levels (5-40% or more as illustrated in the following Examples) that can be tailored to either diagnostic or therapeutic uses. The optimum fluorine content will be determined in each case by the diagnostic requirements for sensitivity on one hand and the extent to which the maximum fluorine substitution does not interfere with the probe's biological or physicochemical properties, e.g., its solubility or receptor binding ability. An important parameter in these considerations will be the type of fluorine substitution and its position on the probe substrate. Generally preferable F levels are 10-40%, and more preferable 20-40%.

Linking of fluorinated residues to biopolymer and polymer starting materials of this invention can be accomplished by a number of reactions, many of which have been described generally in conjugate chemistry (for reviews see, for instance: G. T. Hermanson, *Bioconjugate Chemistry*, Academic Press, New York, 1996; S. S. Wong, *Chemistry of protein conjugation and cross-linking*, CRC Press, Boca Raton, 1993; R. L. Lundblad, *Techniques in Protein Modification*, CRC Press, Boca Raton, 1994; C. F. Meares (ed.), *Perspectives in Bioconjugate Chemistry*, American Chemical Society, Washington, 1993).

A terminal hydroxyl group on the biopolymers and polymers of this disclosure can be allowed to react with bromoacetyl chloride to form a bromoacetyl ester that in turn is allowed to react with an amine precursor to form the -NH-CH<sub>2</sub>-C(O)- linkage. A terminal hydroxyl group also can be allowed to react with 1,1'-carbonyl-bisimidazole and this intermediate in turn allowed to react with an amino precursor to form a -NH-C(O)O- linkage (see Bartling et al., *Nature*, **243**, 342, 1973). A terminal hydroxyl also can be allowed to react with a cyclic anhydride such as succinic anhydride to yield a half-ester which, in turn, is allowed to react with a precursor of the formula C<sub>x</sub>F<sub>y</sub>H<sub>z</sub>-NH<sub>2</sub> using conventional peptide condensation techniques such as dicyclohexylcarbodiimide, diphenylchlorophosphonate, or 2-chloro-4,6-dimethoxy-1,3,5-triazine (see e.g., Means et al., *Chemical Modification of Proteins*, Holden-Day, 1971). A terminal hydroxyl group can also be allowed to react with 1,4-butanediol diglycidyl ether to form an intermediate having a terminal epoxide function linked to the polymer through an ether bond. The terminal epoxide function, in turn, is allowed to react with an amino or hydroxyl precursor (Pitha et al., *Eur. J. Biochem.*, **94**, 11, 1979; Elling and Kula, *Biotech. Appl. Biochem.*, **13** 354, 1991; Stark and Holmberg, *Biotech. Bioeng.*, **34**, 942, 1989).

Halogenation of a hydroxyl group permits subsequent reaction with an alkanediamine such as 1,6-hexanediamine. The resulting product then is allowed to react with carbon disulfide in the presence of potassium hydroxide, followed by the addition of propionyl chloride to generate a isothiocyanate that in turn is allowed to react with an amino precursor to yield a -N-C(S)-N--(CH<sub>2</sub>)<sub>6</sub>-NH- linkage (see e.g., Means et al., *Chemical Modification of Proteins*, Holden-Day, 1971).

A carboxylic acid group of the biopolymers and polymers can be activated with N,N'-dicyclohexylcarbodiimide and then allowed to react with an amino or hydroxyl group to form an amide or ether respectively. Anhydrides and acid chlorides will produce the same links with amines and alcohols. Alcohols can be activated by carbonyldiimidazole and then linked to amines to produce urethane linkages. Alkyl halides can be converted to an amine or allowed to react with an amine, diamines, alcohols, or diols. A hydroxy group can be oxidized to form the corresponding aldehyde or ketone. This aldehyde or ketone then is allowed to react with a precursor carrying a terminal amino group to form an imine that, in turn, is reduced with sodium borohydride or sodium cyanoborohydride to form the secondary amine (see Kabanov et al., *J. Controlled Release*, **22**, 141, 1992; *Methods Enzymology*, XLVII, Hirs & Timasheff, eds., Academic Press, 1977). The precursor terminating in an amino group can also be allowed to react with an alkanolic acid or fluorinated alkanolic acid, preferably an activated derivative thereof, such as an acid chloride or anhydride, to form a linking group -CONH-. Alternatively, an amino precursor can be treated with an  $\alpha$ - $\omega$ -diisocynoalkane to produce a -NC(O)NH(CH<sub>2</sub>)<sub>6</sub>NHC(O)-N- linkage (see Means, *Chemical Modification of Proteins*, Holden-Day, 1971). Furthermore, linkages that are unsymmetrical, such as -CONH- or -NHCO-, can be present in the reverse orientation; e.g., -NHCO- and -OCONH-, respectively. Examples of an activated carbonyl group include anhydride, ketone, p-nitrophenylester, N-hydroxysuccinimide ester, pentafluorophenyl ester and acid chloride.

Suitable fluorinated starting materials for making the novel compositions of the present invention include, but are not limited to inorganic fluorinating agents, such as trifluoromethylhypofluorite, sulfur tetrafluoride or potassium fluoride, organic fluorinating agents, such as Selectfluor<sup>TM</sup>, fluoroalkylcarboxylic acids, fluoroalkylaldehydes, anhydrides, esters, ketones, acid chlorides of fluoroalkylcarboxylic acids, such as monofluoroacetic acid, difluoroacetic acid, trifluoroacetic acid, pentafluoro-propionic acid, heptafluorobutyric acid, heptafluorobutyric anhydride, heptafluorobutyrylchloride, nonafluoropentanoic acid, tridecafluoroheptanoic acid, pentadecafluorooctanoic acid, heptadecafluorononanoic acid, nonadecafluorodecanoic acid, perfluorododecanoic acid, perfluorotetradecanoic acid; fluoroalkanols, such as 2,2,3,3,4,4,4-heptafluoro-1-butanol, 2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,11-heneicosafuoro-1-undecanol, 2,2,3,3,4,4,5,5,6,6,7,7,8,9,9,9-hepta-decafluoro-1-nonanol, 2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-penta-decafluoro-1-octanol, 2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-nonadeca-fluoro-1-decanol, Krytox and Zonyl derivatives, fluoroarylesters, fluoroalkylamines, fluoroarylamines, fluorinated polymers containing reactive terminal groups, fluoroalkyl halides, such as perfluoroethyl iodide, perfluoropropyl iodide, perfluorohexyl bromide, perfluoroheptyl bromide, perfluorooctyl bromide, perfluorodecyl iodide, perfluorooctyl iodide, 1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8-heptadecafluoro-10-iododecane, 1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8-heptadecafluoro-10-iododecane, polytetrafluoroethyleneoxide-co-difluoromethyleneoxide- $\alpha$ , $\omega$ -bis(methylcarboxylate),

dihydroxy-propanoxymethyl derivatives of perfluoropolyoxyalkane, hydroxypolyethylenoxy derivatives of perfluoropolyoxyalkane and the like. Suitable modification procedures have been described in several monographs (J. J. Clark, D. Walls, T. W. Bastock, *Aromatic Fluorination*, CRC Press, Boca Raton, FL, 1996; M. Hudlicky, A. E. Pavlath, *Chemistry of Organic Fluorine Compounds*, ACS, Washington, DC 1995; M. Howe-Grant ed., *Fluorine Chemistry, A Comprehensive Treatment*, Wiley, New York, 1995; G. A. Olah, G. K. Sarya Prakash, R. D. Chambers, eds. *Synthetic Fluorine Chemistry*, Wiley, New York, 1992).

The present invention also contemplates paramagnetic polymers for those polymers capable of forming salts or conjugates with paramagnetic ions. Suitable paramagnetic ions include any paramagnetic ion of the transition metal or lanthanide series, including gadolinium (III), iron (III), manganese (II and III), chromium (III), copper (II), dysprosium (III), terbium (III), holmium (III), erbium (III), and europium (III); most preferred are gadolinium (III), dysprosium (III), iron (III), and manganese (II). The magnetic materials of this invention can be used as contrast-enhancing agents for *in vivo* MR imaging and magnetic resonance angiography.


Specific compounds of Formulas I-XX may require the use of protecting or blocking groups to enable their successful elaboration into the desired structure. Protecting groups may be chosen with reference to Greene, T. W., et al., *Protective Groups in Organic Synthesis*, John Wiley & Sons, Inc., 1991. The blocking groups are readily removable, i.e., they can be removed, if needed, by procedures that will not cause cleavage or other disruption of the remaining portions of the molecule. Such procedures include chemical and enzymatic hydrolysis, treatment with chemical reducing or oxidizing agents under mild conditions, treatment with fluoride ion, treatment with a transition metal catalyst and a nucleophile, and catalytic hydrogenation.

Examples of suitable hydroxyl protecting groups are: trimethylsilyl, triethylsilyl, o-nitrobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, t-butyldiphenylsilyl, t-butyldimethylsilyl, benzyloxycarbonyl, t-butyloxycarbonyl, 2,2,2-trichloroethyloxycarbonyl, and allyloxycarbonyl. Examples of suitable carboxyl protecting groups are benzhydryl, o-nitrobenzyl, p-nitrobenzyl, 2-naphthylmethyl, allyl, 2-chloroallyl, benzyl, 2,2,2-trichloroethyl, trimethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, 2-(trimethylsilyl) ethyl, phenacyl, p-methoxybenzyl, acetonyl, p-methoxyphenyl, 4-pyridylmethyl and t-butyl.


The compounds used in the method of the invention can be prepared readily according in the following detailed examples using readily available starting materials, reagents and conventional synthetic procedures. Additional variants are also possible that are known to those of ordinary skill in this art, but which are not mentioned in greater detail. The following examples illustrate the practice of the present invention but should not be construed as limiting its scope.

Example 1 — N-[3-[2-(Perfluorohexyl)-2-ethoxy]-2-hydroxypropyl]  $\gamma$ -Polyglutamic Acid

A solution of 3-[2-(perfluorohexyl)-2-ethoxy]-1,2-epoxypropane in methylene chloride (0.6 equivalents) was added to  $\gamma$ -polyglutamic acid and stirred at ambient temperature for 6 hours. The suspension was filtered, washed with methylene chloride and acetone, dialyzed and dried, yielding 3-[2-(perfluorohexyl)-2-ethoxy]-2-hydroxypropyl  $\gamma$ -polyglutamic acid with F 13.38%.



Example 2 — 3-[2-(Perfluorohexyl)-2-ethoxy]-2-hydroxypropyl Hyaluronic Acid

An aqueous solution of hyaluronic acid was treated with 3-[2-(perfluorohexyl)-2-ethoxy]-1,2-epoxypropane (0.6 equivalents) and the resulting viscous paste was stirred at ambient temperature for 6 hours. The reaction mixture was precipitated with acetone, washed with acetone, filtered, dialyzed and dried, yielding 3-[2-(perfluorohexyl)-2-ethoxy]-2-hydroxypropyl hyaluronate with F 33.12%.

Example 3 — 3-[2-(Perfluorohexyl)-2-ethoxy]-2-hydroxypropyl Maltodextrin



An aqueous solution of maltodextrin was treated with NaOH (1.3 equivalents) and then with 3-[2-(perfluorohexyl)-2-ethoxy]-1,2-epoxypropane in DMSO (0.6 equivalents) and the resulting viscous paste was stirred at ambient temperature for 6 hours. The reaction mixture was precipitated with acetone, washed with acetone, filtered, dialyzed and dried, yielding 3-[2-(perfluorohexyl)-2-ethoxy]-2-hydroxypropyl maltodextrin with F 21.52%.

20




#### Example 4 — Perfluorophenylhydrazone Carboxymethyl Cellulose

A solution of perfluorophenylhydrazine in DMSO (0.6 equivalents) was added to an aqueous solution of carboxymethyl cellulose and stirred at ambient temperature for 6 hours. The suspension was filtered, washed with methylene chloride and acetone, dialyzed and dried, yielding perfluorophenylhydrazone CMC with F 18.94%.




#### Example 5 — Di- $\alpha,\omega$ -(heptafluorobutyl) Polyethylene Glycol

A solution of heptafluorobutyl chloride in dioxane (0.6 equivalents) was added to polyethylene glycol (Mw 1,000) in dioxane containing triethylamine (0.6 equivalents) and stirred at ambient temperature for 6 hours. The reaction mixture was precipitated in ether, and the crude fluorinated PEG product was chromatographed on silica gel, yielding heptafluorobutyl PEG with F 19.95%.




#### Example 6 — Perfluoroaniline Hyaluronate

A solution of perfluoroaniline (1.6 equivalents) in DMSO was added to an aqueous solution of sodium hyaluronate and stirred at 40°C for 4 hours. The reaction mixture was cooled, treated with sodium cyanoborohydride (10 equivalents) for 9 hours, precipitated with acetone, washed with acetone, filtered, dialyzed and dried, yielding perfluoroaniline hyaluronate with F 17.75%.




#### Example 7 — Perfluorohexanoate Hyaluronate

Sodium hyaluronate was dissolved in water and the pH of the solution was adjusted to pH 4.75 by addition of 0.1 N HCl. Then EDC (1.5 equivalents) was added followed by methylperfluorohexanoate methyl ester (1.05 equivalents). The pH of the reaction mixture then rises to 6.2 over two hours. The reaction mixture was kept at room temperature for five hours, after which it forms a thick insoluble hydrogel. This hydrogel is dialyzed with a 1 M NaCl solution and lyophilized to yield perfluorohexanoate hyaluronate F 29.52%.



#### Example 8 — Trifluoroacetate Hydroxypropyl Cellulose

A solution of ethyl trifluoroacetate in pyridine (1.6 equivalents) was added to a pyridine solution of hydroxypropyl cellulose and stirred at ambient temperature for 9 hours. The solution was precipitated in ice water, filtered, washed with methanol and acetone, dialyzed and dried, yielding trifluoroacetate hydroxypropyl cellulose with F 34.56%.




$R = H, \text{OCOCF}_3, \text{CH}_2\text{CH}(\text{OCOCF}_3)\text{CH}_3$

$n=3-10,000$

#### Example 9 — 3-(Perfluoro-n-octyl)-2-hydroxypropyl Hyaluronic Acid

An aqueous solution of hyaluronic acid was treated with 3-(perfluoro-n-octyl)-1,2-epoxypropane (1.2 equivalents) and the resulting viscous paste was stirred at ambient

temperature for 6 hours. The reaction mixture was precipitated with acetone, washed with acetone, filtered, dialyzed and dried, yielding 3-(perfluoro-n-octyl)-2-hydroxypropyl hyaluronate with F 31.52%.




R = H,  $\text{CF}_3(\text{CF}_2)_7\text{CH}_2\text{CH}(\text{OH})\text{CH}_2-$

n=1-4,000

Example 10 — Perfluoro-2,5,8,11-tetramethyl-3,6,9,12-tetraoxopentadecanoate Hyaluronic Acid

An aqueous solution of hyaluronic acid was treated with perfluoro-2,5,8,11-tetramethyl-3,6,9,12-tetraoxopentadecanoic acid methyl ester (1.2 equivalents) and catalytic amounts of sulfuric acid and the resulting viscous paste was stirred at ambient temperature for 14 hours. The reaction mixture was washed with acetone, filtered, dialyzed and dried, yielding perfluoro-2,5,8,11-tetramethyl-3,6,9,12-tetraoxopentadecanoate hyaluronate with F 34.65%.




R = H,  $\text{COCF}(\text{CF}_3)[\text{OCF}_2\text{CF}(\text{CF}_3)]_3\text{O}(\text{CF}_2)_2\text{CF}_3$

n=1-8,000

Example 11 — 4,4,4-Trifluoro-3-hydroxy-3-(trifluoromethyl)butanoate Hydroxypropyl Cellulose

An aqueous solution of 4,4,4-trifluoro-3-hydroxy-3-(trifluoromethyl)butyric acid (3.2 equivalents) was acidified to pH 4.75 and treated with EDC (3.5 equivalents) followed by hydroxypropyl cellulose in water and the resulting viscous paste was stirred at ambient temperature for 14 hours. The reaction mixture was dialyzed and lyophilized, yielding 4,4,4-trifluoro-3-hydroxy-3-(trifluoromethyl)butanoate hydroxypropyl cellulose with F 28.76%.

23



R = H, OCOCH(OH)(CF<sub>3</sub>)<sub>2</sub>,  
CH<sub>2</sub>CH[OCOCH(OH)(CF<sub>3</sub>)<sub>2</sub>]CH<sub>3</sub>


n=3-10,000

5

Example 12 — 4,4,4-Trifluoro-3-hydroxy-3-(trifluoromethyl)butanoate Dextran

An aqueous solution of 4,4,4-trifluoro-3-hydroxy-3-(trifluoromethyl)butyric acid (4.2 equivalents) was acidified to pH 4.75 and treated with EDC (4.5 equivalents) followed by dextran (Mw 500,000) in water and the resulting paste was stirred at ambient temperature for 14 hours. The reaction mixture was precipitated with acetone, filtered, redissolved in water, dialyzed and lyophilized, yielding 4,4,4-trifluoro-3-hydroxy-3-(trifluoromethyl)butanoate dextran with F 24.57%.

10



R = H, O[COCH(OH)(CF<sub>3</sub>)<sub>2</sub>]CH<sub>3</sub>

n=2-25,000

15


Example 13 — Trifluoroacetate Collagen

A solution of ethyl trifluoroacetate in pyridine (1.6 equivalents) was added to a pyridine solution of collagen and stirred at ambient temperature for 6 hours. The solution was dialyzed and lyophilized, yielding trifluoroacetate collagen with F 23.16%.

20



24



$R = H, COCF_3; R_1 = H, OH, COCF_3;$   
 $R_2 = H, CH_3; R_3 = OH, COCF_3, NHR_1$


$m = 0.1-0.2 \quad n = 0.25-0.4 \quad p = 0.1-0.2$

wherein  $m+n+p = \sim 0.5$

#### 5 Example 14 — Trifluoroacetate Poly(vinyl alcohol)

A solution of trifluoroacetic anhydride in pyridine (1.2 equivalents) was added to a pyridine solution of poly(vinyl alcohol) (Mw 30,000) and stirred at ambient temperature for 6 hours. The solution was precipitated with ice water, dialyzed and lyophilized, yielding trifluoroacetate PVA with F 39.98%.


10



#### 15 Example 15 — Heptafluorobutyl Polyethylene Imine

A solution of heptafluorobutyl chloride in DMSO (2.6 equivalents) was added to a DMSO solution of polyethylene imine (Mw 70,000) containing triethylamine (2.6 equivalents) and stirred at ambient temperature for 6 hours. The reaction mixture was dialyzed, yielding heptafluorobutyl PEI with F 45.35%.

20



$m = 0-0.3 \quad n = 0.1-1.0 \quad p = 0-0.3 \quad v = 0-0.3$

wherein  $m+n+p+v = 1$

Example 16 — Superparamagnetic Iron Oxide Hyaluronate Particles

To a stirred dispersion of superfine iron oxide particles (3 nanometer, 0.5 g) in water (50 mL) was added an aqueous solution of sodium hyaluronate (50 mg, 5 mL). The dispersion was sonicated, centrifuged and the supernatant filtered through 0.22  $\mu\text{m}$  filter. A magnetization curve revealed that the hyaluronate particles were superparamagnetic.

Example 17 — Paramagnetic Gadolinium Hyaluronate Beads

To a rapidly stirred, aqueous solution of gadolinium (III) acetate (1.1 equivalents) was added dropwise an aqueous solution of sodium hyaluronate through a syringe. The resulting gel beads were centrifuged, dialyzed and lyophilized. A magnetization curve revealed that the hyaluronate particles were paramagnetic.

Use of new biocompatible materials and probes

The fluorine-modified biopolymers of the instant invention are useful as diagnostic tools (MRI, NMR and the like). As illustrated by the Examples, the methods of the instant invention permit the preparation of diagnostic agents with dual functionalities. Thus, the simultaneous incorporation of  $^{19}\text{F}$  or superparamagnetic residues and fluorescent moieties into biopolymers and polymers affords diagnostic probes that can be employed for both MRI and fluorescent studies. Examples of such dual function diagnostic probes are those biopolymers and polymers that contain both a fluorine moiety as described herein and a fluorescent moiety or a fluorinated fluorescent moiety such as: 4-trifluoromethyl-7-aminocoumarin, 4-trifluoromethyl-umbelliferone (or its acetate or butyrate derivatives), 4-fluoro-7-sulfamyl-benzofurazam, certain BODIPY dyes, e.g., N-(4,4'-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-yl)-methyliodoacetamide, N-(4,4'-difluoro-1,3,5,7-tetramethyl-4-bora-3a,4a-diaza-s-indacene-2-yl)-iodoacetamide and 4,4'-difluoro-5-phenyl-4-bora-3a,4a-diaza-s-indacene-3-propionic acid, 3-chloro-1-(3-chloro-5-(trifluoromethyl)-2-pyridimyl)-5-(trifluoromethyl)-2[1H]-pyridinone, 6-carboxymethylthio-2',4',5',7'-tetrabromo-4,5,7-trifluorofluorescein (Eosin F3S), and Oregon Green carboxylic acid.

The fluorinated polymers of the present invention display sensitivity in their  $T_1$  relaxation times to different oxygen partial pressures ( $\text{pO}_2$ ), producing linear correlation over a range of  $\text{pO}_2$ . This demonstrates their potential utility as oxygen sensitive imaging probes. The fluorinated polymers also display chemical shift and temperature sensitivity, indicating their utility as temperature sensitive imaging probes. These novel agents of this invention are suitable for many diagnostic uses, and provide the ability to image *in vivo* or non-invasively monitor tissues, organs and cellular implants, for example, pancreatic islet  $\beta$ -cells that are encapsulated with the present fluorinated polymers, and measure their mass, function, viability or evidence of inflammation. Additionally, engraftment of transplanted isolated pancreatic islets can be monitored, using, for example, islets labeled with  $\beta$ -cell specific oxygen-sensitive fluorinated probes.  $^{19}\text{F}$ -MRI with these novel agents permits monitoring of

other disorders, such as cancer, the comparison of normal or diseased cells, organs or tissues, the viability of transplanted cells or other tissues when those fluorinated agents have specificity for target tissues. This new methodology is instrumental in the development of clinical examinations for monitoring disease progress and response to therapy in diabetics and in people strongly at risk for diabetes and other patient populations.

The paramagnetic polymers of the present invention are used as contrast agents and are administered orally (or elsewhere in the gastrointestinal tract), intravascularly or intraperitoneally in physiological buffer or other physiologically acceptable carriers. The dosage depends on the sensitivity of the NMR imaging instrumentation and on the composition of the contrast agent. Thus, a contrast agent containing a highly paramagnetic substance, e.g., gadolinium (III), generally requires a lower dosage than a contrast agent containing a paramagnetic substance with a lower magnetic moment, e.g., iron (III). In general, dosage will be in the range of about 0.001-1 mmol/kg, more preferably about 0.01-0.1 mmol/kg. In one embodiment, the products are dispersed in a suitable injection medium, such as distilled water or normal saline, to form a dispersoid that is introduced into the subject's vascular system by intravenous injection. The particles are then carried through the vascular system to the target organ where they are taken up.

When intravascularly administered, the paramagnetic compounds will be preferentially taken up by organs which ordinarily function to cleanse the blood of impurities, notably the liver, spleen, and lymph nodes, and the other organs which tend to accumulate such impurities, notably bone and neural tissue and to some extent, lung. In each of these organs and tissues, the uptake into the reticuloendothelial cells will occur by phagocytosis, wherein the paramagnetic compounds enter the individual cells in membrane-bound vesicles; this permits a longer half-life in the cells, as such membrane-bound paramagnetic compounds will not tend to clump or aggregate (aggregates are rapidly metabolized and cleared from the organ/tissue). Other uptake mechanisms are possible, e.g., pinocytosis. Also, it is possible that the other cells of the liver (hepatocytes) may absorb the paramagnetic compounds. Because cancerous tumor cells can lack the ability of phagocytic uptake, the intravascularly administered particles can serve as valuable tools in the diagnosis of cancer in the above-mentioned organs, as tumors will be immediately distinguishable on any image obtained. In another embodiment, the paramagnetic compounds are administered as dispersoids into the gastrointestinal tract, which includes the esophagus, stomach, large and small intestine, either orally, by intubation, or by enema, in a suitable medium such as distilled water. The paramagnetic compounds are preferentially absorbed by the cells of the tract, especially those of the intestine and, like the intravascularly introduced paramagnetic compounds, will exert an effect on  $T_2$  of the organ or tissue. In this manner, cancers and other debilitating diseases of the digestive system such as ulcers can be diagnosed and affected areas pinpointed.

The new compositions of this disclosure also display unusual surfactant and emulsification properties.

5 All patents, patent applications, provisional applications, and publications referred to or cited herein are incorporated by reference in their entirety, including all figures and tables, to the extent they are not inconsistent with the explicit teachings of this specification.

10

15

20

25

30

35

References


1. US PAT 6,019,959 February 1, 2000. Oligomeric compounds that contain perfluoroalkyl, process for their production, and their use in NMR diagnosis  
5 INVENTOR(S)- Platzek, Johannes; Niedballa, Ulrich; Raduchel, Bernd; Schlecker, Wolfgang; Weinmann, Hanns-Joachim; Frenzel, Thomas; Misselwitz, Bernd; Ebert, Wolfgang  
PATENT ASSIGNEE(S)- Schering Aktiengesellschaft
2. US PAT 5,798,406 dated August 25, 1998. Fluorinated acrylic and methacrylic latices and mixtures thereof, processes for manufacturing them and their applications in the field of hydrophobic coatings  
10 INVENTOR(S)- Feret; Bruno; Sarrazin; Laure; Vanh  ye; Didier  
PATENT ASSIGNEE(S)- Elf Atochem S.A
3. U.S. Patent 5,902,795, 1999. Oligosaccharides reactive with hyaluronan-binding protein, monoclonal antibodies recognizing hyaluronan-binding protein, and use in cancer therapy  
15 INVENTOR(S)- B. P. Toole, S.D. Banerjee  
PATENT ASSIGNEE(S)-
4. US PAT 6,218,464 dated April 17, 2001 Preparation of fluorinated polymers  
20 INVENTOR(S)- Parker, Hsing-Yeh; Lau, Willie; Rosenlind, Erik S.  
PATENT ASSIGNEE(S)- Rohm and Haas Company
5. US PAT 5652347 dated: July 29, 1997 Method for making functionalized derivatives of hyaluronic acid  
25 INVENTOR(S)- Pouyani, Tara; Prestwich, Glenn D.  
PATENT ASSIGNEE(S)- The Research Foundation of State University of New York
6. US PAT 6,203,777 dated March 20, 2001 Method of contrast enhanced magnetic resonance imaging using carbohydrate particles  
30 INVENTOR(S)- Schroder, Ulf  
PATENT ASSIGNEE(S)- Nycomed Imaging AS (Oslo, NO)
7. US PAT 5,824,335 dated October 20, 1998 Non-woven fabric material comprising auto-crosslinked hyaluronic acid derivatives  
35 INVENTOR(S)- Dorigatti, Franco; Callegaro, Lanfranco; Romeo, Aurelio  
PATENT ASSIGNEE(S)-

8. US PAT 6,245,319 dated June 12, 2001 Colloidal dispersions of perfluoropentane  
INVENTOR(S)- Quay, Steven C.  
PATENT ASSIGNEE(S)- Sonus Pharmaceuticals, Inc.
- 5 9. US PAT 5,155,194 dated October 13, 1992 Hydrogels based on fluorine-containing and  
saccharide monomers  
INVENTOR(S)- Kossmehl, Gerhard; Schafer, Horst; Klaus, Norbert, Volkheimer; Jurgen;  
Rezaii-Djafari, Madjid  
PATENT ASSIGNEE(S)- Ciba-Geigy Corporation
- 10 10. US PAT 6,274,677 dated August 14, 2001 Process for the producing perfluorovinyl  
ethersulfonic acid derivatives and copolymer of the same  
INVENTOR(S)- Tatemoto; Masayoshi  
PATENT ASSIGNEE(S)- Daikin Industries Ltd.
- 15 11. US PAT 6,156,937 dated December 5, 2000 Functionalized fluoropolyethers  
INVENTOR(S)- Marchionni, Giuseppe; Gavezotti, Piero; Strepparola, Ezio  
PATENT ASSIGNEE(S)- Ausimont S.p.A.
- 20 12. US PAT 6,054,492 dated April 25, 2000 Fluorinated copolymeric pharmaceutical adjuncts  
INVENTOR(S)- Kabanov, Alexander V.; Vinogradov, Serguei V.  
PATENT ASSIGNEE(S)- Supratek Pharma Inc.

Claims

I claim:

1. A fluorinated biopolymer comprising a compound of any of the Formulas I-VIII:



where

for Formula I:

 $R_1$  represents H, X;  $R_2$  represents H, X;  $R_3$  represents H, OH, OY, OX, NHX

for Formula II:

 $R_1$  represents H, X;  $R_2$  represents H, X;  $R_3$  represents H, OY, OX, NHX

For Formula III:

R<sub>1</sub> represents H, X; R<sub>2</sub> represents H, X; R<sub>3</sub> represents H, Y, X

for Formula IV:

R<sub>1</sub> represents H, X; R<sub>2</sub> represents H, X; R<sub>3</sub> represents CO<sub>2</sub>H, CO<sub>2</sub>X, CH<sub>2</sub>X, CH<sub>2</sub>NHX; R<sub>4</sub> represents H, X; R<sub>5</sub> represents H, X; R<sub>6</sub> represents H, X; R<sub>7</sub> represents X, COCH<sub>3</sub>, COX

For Formula V:

R<sub>1</sub> represents H, X; R<sub>2</sub> represents H, X; R<sub>3</sub> represents CO<sub>2</sub>H, CO<sub>2</sub>X, CH<sub>2</sub>X, CH<sub>2</sub>NHX; R<sub>4</sub> represents H, SO<sub>3</sub>H, X; R<sub>5</sub> represents H, SO<sub>3</sub>H, X; R<sub>6</sub> represents H, X; R<sub>7</sub> represents COCH<sub>3</sub>, COX, X

for Formula VI:

R<sub>1</sub> represents H, X; R<sub>2</sub> represents H, X; R<sub>3</sub> represents CO<sub>2</sub>H, CO<sub>2</sub>X, CH<sub>2</sub>X, CH<sub>2</sub>NHX; R<sub>4</sub> represents H, X; R<sub>5</sub> represents SO<sub>3</sub>H, X; R<sub>6</sub> represents H, X; R<sub>7</sub> represents COCH<sub>3</sub>, COX, X

for Formula VII:

R<sub>1</sub> represents H, X; R<sub>2</sub> represents H, X; R<sub>3</sub> represents H, X; R<sub>4</sub> represents SO<sub>3</sub>H, X; R<sub>5</sub> represents SO<sub>3</sub>H, X; R<sub>6</sub> represents H, X; R<sub>7</sub> represents COCH<sub>3</sub>, COX, X

For Formula VIII:

R<sub>1</sub> represents H, X; R<sub>2</sub> represents H, X; R<sub>3</sub> represents CO<sub>2</sub>H, CO<sub>2</sub>X, CH<sub>2</sub>X, CH<sub>2</sub>NHX; R<sub>4</sub> represents H, X; R<sub>5</sub> represents H, X; R<sub>6</sub> represents H, X; R<sub>7</sub> represents H, X; R<sub>8</sub> represents COCH<sub>3</sub>, COX, X


wherein for all of the above Formulas I-VIII

X represents a fluorine containing moiety, a luminescent residue, a fluorescent residue, a fluorinated luminescent residue or a fluorinated fluorescent residue and


Y represents a saccharide branch residue comprised of mono-, di-, oligo- or polysaccharide, or a fluorinated saccharide branch residue comprised of mono-, di-, oligo- or polysaccharide.




## 2. A fluorinated biopolymer comprising a compound of any of Formulas IX and XII




IX



X



XI



XII

wherein

for Formula IX:

$R_1$  represents H, X, Z;  $R_2$  represents H, X, Z;  $R_3$  represents H, X;  $R_4$  represents H, X, Z;  $R_5$  represents H, X;  $R_6$  represents H, X;  $R_7$  represents H, X, Z

for Formula X:

$R_1$  represents H, X,  $\text{CH}_2\text{OGOCO}_2\text{H}$ ,  $\text{CH}_2\text{OGCO}_2\text{X}$ ,  $\text{CH}_2\text{OGCONX}$ ,  $\text{CH}_2\text{OGCH}_2\text{NX}$ ;  $R_2$  represents H, X, Z;  $R_3$  represents H, X,  $\text{CH}_2\text{OGOCO}_2\text{H}$ ,  $\text{CH}_2\text{OGCO}_2\text{X}$ ,  $\text{CH}_2\text{OGCONX}$ ,  $\text{CH}_2\text{OGCH}_2\text{NX}$ ;  $R_4$  represents H,  $\text{COCH}_3$ ,  $\text{COX}$ , X,  $\text{CH}_2\text{OGOCO}_2\text{H}$ ,  $\text{CH}_2\text{OGCO}_2\text{X}$ ,  $\text{CH}_2\text{OGCONX}$ ,  $\text{CH}_2\text{OGCH}_2\text{NX}$

for Formula XI:

$R_1$  represents H, OH, X, OX, OZ,  $\text{CH}_2\text{OGOCO}_2\text{H}$ ,  $\text{CH}_2\text{OGCO}_2\text{X}$ ,  $\text{CH}_2\text{OGCONX}$ ,  $\text{CH}_2\text{OGCH}_2\text{NX}$ ;  $R_2$  represents H, OH, X, OX, OZ,  $\text{CH}_2\text{OGOCO}_2\text{H}$ ,  $\text{CH}_2\text{OGCO}_2\text{X}$ ,  $\text{CH}_2\text{OGCONX}$ ,  $\text{CH}_2\text{OGCH}_2\text{NX}$ ;  $R_3$  represents  $\text{CH}_2\text{OH}$ ,  $\text{CH}_2\text{OX}$ ,  $\text{CH}_2\text{OZ}$ ,  $\text{CH}_2\text{X}$ ,  $\text{CH}_2\text{NHX}$ ,  $\text{CO}_2\text{H}$ ,  $\text{CO}_2\text{X}$ ,  $\text{CONX}$ ,  $\text{CH}_2\text{OGO}$ ,  $\text{CH}_2\text{GOX}$ ,  $\text{CH}_2\text{OGOCO}_2\text{H}$ ,  $\text{CH}_2\text{OGCO}_2\text{X}$ ,  $\text{CH}_2\text{OGCONX}$ ,  $\text{CH}_2\text{OGCH}_2\text{NX}$ ;  $R_4$  represents OH, Z, OX, X; G represents alkyl, hydroxyalkyl

for Formula XII:

K represents H, OH, X, OX, OZ; L represents H, OH, X, OX, OZ; W represents H, OH, X, OX, OZ; T represents H, OH, X, OX, OZ;

V represents anhydrofuranosyl, anhydropyranosyl, and m, n, p, q, r and s represent an integer of 1-500 inclusive;


wherein for all of the above Formulas IX-XII

X represents a fluorine containing moiety, a luminescent residue, a fluorescent residue, a fluorinated luminescent residue or a fluorinated fluorescent residue;

Y represents a saccharide branch residue comprised of mono-, di-, oligo- or polysaccharide, or a fluorinated saccharide branch residue comprised of mono-, di-, oligo- or polysaccharide.

Z represents acyl or alkyl.

### 3. A fluorinated biopolymer of the Formula XIII



XIII

where

for Formula XIII:


K represents H, OH, X, OX, OZ, (Y)<sub>i</sub>; L represents H, OH, X, OX, OZ, (Y)<sub>i</sub>; W represents H, (CH<sub>2</sub>)<sub>d</sub>, CO<sub>2</sub>H, CH, CX, X; T represents H, OH, X, OX, OZ; V represents (CH<sub>2</sub>)<sub>d</sub>, CH<sub>2</sub>OX, CH<sub>2</sub>OZ, CH<sub>2</sub>X, CH<sub>2</sub>NHX; S represents H, O, X, NHX, (Y)<sub>i</sub>; T represents H, O, X, NHX, (Y)<sub>i</sub>; R<sub>1</sub> represents H, X and d represents 1-3 inclusive; f, and n represent 1-1,500 inclusive and for all of the above Formulas:

X represents a fluorine containing moiety, a luminescent residue, a fluorescent residue, a fluorinated luminescent residue or a fluorinated fluorescent residue;


Y represents an amino acid residue or a fluorinated amino acid residue; and

Z represents acyl, alkyl.


## 4. A fluorinated biopolymer comprising a compound of any of Formulas XIV-XX




XIV




XV




XVI




XVII



XVIII



XIX



XX

Where

for Formula XIV:

R<sub>1</sub> represents H, X; R<sub>2</sub> represents H, Z, X.

for Formula XV:

R<sub>1</sub> represents H, CH<sub>3</sub>, (CH<sub>2</sub>)<sub>m</sub>CH<sub>3</sub>, CF<sub>3</sub>, (CF<sub>2</sub>)<sub>m</sub>CF<sub>3</sub>; R<sub>2</sub> represents H, CH<sub>3</sub>, (CH<sub>2</sub>)<sub>m</sub>CH<sub>3</sub>, CF<sub>3</sub>, (CF<sub>2</sub>)<sub>m</sub>CF<sub>3</sub>; R<sub>3</sub> represents H, CH<sub>3</sub>, (CH<sub>2</sub>)<sub>m</sub>CH<sub>3</sub>, CF<sub>3</sub>, (CF<sub>2</sub>)<sub>m</sub>CF<sub>3</sub>; R<sub>4</sub> represents H, CH<sub>3</sub>, (CH<sub>2</sub>)<sub>m</sub>CH<sub>3</sub>, CF<sub>3</sub>, (CF<sub>2</sub>)<sub>m</sub>CF<sub>3</sub>; R<sub>5</sub> represents H, CH<sub>3</sub>, (CH<sub>2</sub>)<sub>m</sub>CH<sub>3</sub>, CF<sub>3</sub>, (CF<sub>2</sub>)<sub>m</sub>CF<sub>3</sub>, CH<sub>2</sub>X, CH<sub>2</sub>NHX; R<sub>6</sub> represents H, CH<sub>3</sub>, (CH<sub>2</sub>)<sub>m</sub>CH<sub>3</sub>, CF<sub>3</sub>, (CF<sub>2</sub>)<sub>m</sub>CF<sub>3</sub>, CH<sub>2</sub>X, CH<sub>2</sub>NHX; m represents 1-10 inclusive; n represents 1-3,000 inclusive;

for Formula XVI:

R<sub>1</sub> represents OH, X, OX, OZ; R<sub>2</sub> represents OH, X, OX, OZ; m and n represent 1-15,000;

for Formula XVII:

R<sub>1</sub> represents O, CH<sub>2</sub>X, CH<sub>2</sub>NHX, OZ; R<sub>2</sub> represents CH<sub>3</sub>, (CH<sub>2</sub>)<sub>m</sub>CH<sub>3</sub>; R<sub>3</sub> represents CH<sub>3</sub>, (CH<sub>2</sub>)<sub>m</sub>CH<sub>3</sub>, CF<sub>3</sub>, (CF<sub>2</sub>)<sub>m</sub>CF<sub>3</sub>; R<sub>4</sub> represents (CH<sub>2</sub>)<sub>n</sub>; R<sub>5</sub> represents (CH<sub>2</sub>)<sub>q</sub>; R<sub>6</sub> represents H, OH, OX, X; R<sub>7</sub> represents H, OH, OX, X; m and n represent 1-30 inclusive; p and q represent 0-3,000;

for Formula XVIII:

$R_1$  represents O, OX,  $CF_3$ ,  $(CF_2)_mCF_3$ ;  $R_2$  represents  $CH_3$ ,  $(CH_2)_nCH_3$ ,  $CF_3$ ,  $(CF_2)_nCF_3$ ;  $R_3$  represents  $CH_3$ ,  $(CH_2)_nCH_3$ ,  $CF_3$ ,  $(CF_2)_nCF_3$ ;  $R_4$  represents  $(CH_2)_m$ ;  $R_5$  represents  $(CH_2)_q$ ;  $R_6$  represents OH, OX, X;  $R_7$  represents H, X; m represents 1 or 2; n represents 1-10 inclusive; p and q represent 1-3,000 inclusive;

For Formula XVIII:

$R_1$  represents H,  $CH_3$ ,  $(CH_2)_mCH_3$ ,  $CF_3$ ,  $(CF_2)_mCF_3$ ;  $R_2$  represents H, OH, OX, X;  $R_3$  represents H, OH, OX, X; m represents 1-30 inclusive; n represents 1-3,000 inclusive;

for Formula XIX:

$R_1$  represents  $CH_2$ ,  $CH_2CH_2$ ,  $CF_2$ ,  $CF_2CF_2$ ;  $R_2$  represents  $CH_2$ ,  $CF_2$ ;  $R_3$  represents OH, OX, OZ;  $R_4$  represents H, X, Z; where Z represents  $Y[(OCH_2CH_2)_m]_q$ ; Y represents a multidentate core, m and n represent 1-80,000 inclusive; and q represents 1-10 inclusive;

for Formula XX:

$R_1$  represents H, X;  $R_2$  represents H, X,  $(CH_2CH_2N)_m$ ,  $(CH_2CH_2NX)_m$ ;  $R_3$  represents H, X,  $(CH_2CH_2N)_m$ ,  $(CH_2CH_2NX)_m$ ;  $R_4$  represents H, X,  $(CH_2CH_2N)_mCH_2CH_2NH_2$ ,  $(CH_2CH_2N)_mCH_2CH_2NHX$ ; m represents 1-3,000 inclusive; n represents 5-80,000;

wherein for all of the above Formulas

X represents a fluorine containing moiety, a luminescent residue, a fluorescent residue, a fluorinated luminescent residue or a fluorinated fluorescent residue; and


Z represents acyl or alkyl.

5. The fluorinated biopolymer, according to claim 1, which is also paramagnetic.

6. The fluorinated biopolymer of any of claim 1, wherein X is fluoroalkyl, fluoroaryl, fluoroacyl, perfluoroalkyl, perfluoroaryl, perfluoroacyl, perfluoropolymer, fluoroamine, fluorocarbamate, fluorotriazine, fluorosulfonylalkyl derivatives,  $CF_2Cl$ ,  $SO_2[CF_2]_xCF_3$ , F,  $CF_3$ ,  $COC_xF_y$ ,  $C_xF_yH_z$ ,  $[(CH_2)_mO]_x(CH_2CF_2O)_y(CF_2CF_2O)_z(CF_2)_2CF_2CH_2O(CH_2)_pOH$ ,  $CH_2C(OH)C_xF_yH_z$ ,  $C_xF_yH_zO_p$ ,  $COC_xF_yH_z$ ,  $OCH_2C_xF_z[C_xF_zO]_mF$ ,  $CH_2C(CH_3)CO_2C_xH_z(CF_2)_mCF_3$ ,  $CH_2(CF_2O)_x(CF_2CF_2O)_y(CF_2O)_zCF_2CH_2OH$ ,  $COCF(CF_3)-[CF(CF_3)CF_2O]_mF$ ,  $NHC_xF_yH_zO_p$ ,  $CH_2CF_2O[CF_2CF_2O]_m(CF_2OCF_2CH_2OH)$ ,  $COC_xH_z(CF_2)_mCF_3$ ,  $COCF_2O[CF_2CF_2O]_nCF_2OCF_2CO_2H$ ,  $[(CH_2)_mO]_x(CH_2CF_2O)_y(CF_2CF_2O)_zCF_2CH_2O(CH_2)_pOH$ ,  $N[C_xF_yH_z]_p$ ,  $C_xH_zCO_2C_xH_z(CF_2)_mCF_3$ ,  $COC_xF_y[C_xF_zO]_mF$ , and m, x, y, z are integers from 1 to 150 inclusive.


7. A fluorinated biopolymer comprising a polymeric compound selected from the group consisting of:

- a. 3-[2-(perfluorohexyl)-2-ethoxy]-2-hydroxypropyl  $\gamma$ -polyglutamic acid of the formula:





wherein  $[m + n = 1]_q$   $q = 5-70,000$ ;



- b. 3-[2-(perfluorohexyl)-2-ethoxy]-2-hydroxypropyl hyaluronate of the formula




- c. 3-[2-(perfluorohexyl)-2-ethoxy]-2-hydroxypropyl maltodextrin of the formula



- d. perfluorophenylhydrazone carboxymethylcellulose of the formula




e. di- $\alpha$ , $\omega$ -(heptafluorobutyl) polyethylene glycol of the formula




$$n=1-50,000$$

f. perfluoroaniline hyaluronate of the formula





$$n=1-4,000$$

g. perfluorohexanoate hyaluronate of the formula



$$n=1-8,000$$


h. trifluoroacetate hydroxypropyl cellulose of the formula



$$n=3-10,000$$

i. 3-(perfluoro-n-octyl)-2-hydroxypropyl hyaluronic acid of the formula

38




$$R = H, CF_3(CF_2)_7CH_2CH(OH)CH_2-$$

$$n=1-4,000$$

and salts thereof;

j. perfluoro-2,5,8,11-tetramethyl-3,6,9,12-tetraoxopentadecanoate hyaluronic acid of the formula




$$R = H, COCF(CF_3)[OCF_2CF(CF_3)]_3O(CF_2)_2CF_3$$

$$n=1-8,000$$

and salts thereof;

k. 4,4,4-trifluoro-3-hydroxy-3-(trifluoromethyl)butanoate hydroxypropyl cellulose of the formula




$$R = H, OCOCH(OH)(CF_3)_2, CH_2CH[OCOCH(OH)(CF_3)_2]CH_3$$

$$n=3-10,000$$

l. 4,4,4-trifluoro-3-hydroxy-3-(trifluoromethyl)butanoate dextran of the formula


39



$$R = H, O[COCH(OH)(CF_3)_2]CH_3$$

$$n=2-25,000$$

m. trifluoroacetate collagen of the formula




$$R = H, COCF_3; R_1 = H, OH, OCOCF_3;$$

$$R_2 = H, CH_3; R_3 = OH, OCOCF_3, NHR_1$$

$$m = 0.1-0.2 \quad n = 0.25-0.4 \quad p = 0.1-0.2$$


wherein  $m + n + p = 1$

n. trifluoroacetate poly(vinyl alcohol) of the formula



$$m=20-10,000$$

o. heptafluorobutyl polyethylene imine of the formula





$$m = 0-0.3 \quad n = 0.1-1.0 \quad p = 0-0.3 \quad v = 0-0.3$$

$$m + n + p + v = 1$$

- p. superparamagnetic iron oxide hyaluronate particles; and
- q. paramagnetic gadolinium hyaluronate beads.

8. A method of improving the effectiveness of magnetic resonance imaging (MRI) which comprises:

- a. administering an effective amount of one or more fluorinated and/or paramagnetic polymers of claims 1-4 to a patient;
- b. subjecting the patient to an MRI of a tissue/organ where the administered polymer is expected to accumulate; and
- c. evaluating the tissue/organ from the MRI images obtained.

9. The fluorinated biopolymer of any of claim 2, wherein X is fluoroalkyl, fluoroaryl, fluoroacyl, perfluoroalkyl, perfluoroaryl, perfluoroacyl, perfluoropolymer, fluoroamine, fluorocarbamate, fluorotriazine, fluorosulfonylalkyl derivatives,  $\text{CF}_2\text{Cl}$ ,  $\text{SO}_2[\text{CF}_2]_x\text{CF}_3$ , F,  $\text{CF}_3$ ,  $\text{COC}_x\text{F}_y$ ,  $\text{C}_x\text{F}_y\text{H}_z$ ,  $[(\text{CH}_2)_m\text{O}]_x(\text{CH}_2\text{CF}_2\text{O})_y(\text{CF}_2\text{CF}_2\text{O})_z(\text{CF}_2)_2\text{CF}_2\text{CH}_2\text{O}(\text{CH}_2)_p\text{OH}$ ,  $\text{CH}_2\text{C}(\text{OH})\text{C}_x\text{F}_y\text{H}_z$ ,  $\text{C}_x\text{F}_y\text{H}_z\text{O}_p$ ,  $\text{COC}_x\text{F}_y\text{H}_z$ ,  $\text{OCH}_2\text{C}_x\text{F}_z[\text{C}_x\text{F}_2\text{O}]_m\text{F}$ ,  $\text{CH}_2\text{C}(\text{CH}_3)\text{CO}_2\text{C}_x\text{H}_z(\text{CF}_2)_m\text{CF}_3$ ,  $\text{CH}_2(\text{CF}_2\text{O})_x(\text{CF}_2\text{CF}_2\text{O})_y(\text{CF}_2\text{O})_z\text{CF}_2\text{CH}_2\text{OH}$ ,  $\text{COCF}(\text{CF}_3)-[\text{CF}(\text{CF}_3)\text{CF}_2\text{O}]_m\text{F}$ ,  $\text{NHC}_x\text{F}_y\text{H}_z\text{O}_p$ ,  $\text{CH}_2\text{CF}_2\text{O}[\text{CF}_2\text{CF}_2\text{O}]_m(\text{CF}_2\text{OCF}_2\text{CH}_2\text{OH})$ ,  $\text{COC}_x\text{H}_z(\text{CF}_2)_m\text{CF}_3$ ,  $\text{COCF}_2\text{O}[\text{CF}_2\text{CF}_2\text{O}]_n\text{CF}_2\text{OCF}_2\text{CO}_2\text{H}$ ,  $[(\text{CH}_2)_m\text{O}]_x(\text{CH}_2\text{CF}_2\text{O})_y(\text{CF}_2\text{CF}_2\text{O})_z\text{CF}_2\text{CH}_2\text{O}(\text{CH}_2)_p\text{OH}$ ,  $\text{N}[\text{C}_x\text{F}_y\text{H}_z]_p$ ,  $\text{C}_x\text{H}_z\text{CO}_2\text{C}_x\text{H}_z(\text{CF}_2)_m\text{CF}_3$ ,  $\text{COC}_x\text{F}_y[\text{C}_p\text{F}_2\text{O}]_m\text{F}$ , and m, x, p, y, z are integers from 1 to 150 inclusive.

10. The fluorinated biopolymer of any of claim 3, wherein X is fluoroalkyl, fluoroaryl, fluoroacyl, perfluoroalkyl, perfluoroaryl, perfluoroacyl, perfluoropolymer, fluoroamine, fluorocarbamate, fluorotriazine, fluorosulfonylalkyl derivatives,  $\text{CF}_2\text{Cl}$ ,  $\text{SO}_2[\text{CF}_2]_x\text{CF}_3$ , F,  $\text{CF}_3$ ,  $\text{COC}_x\text{F}_y$ ,  $\text{C}_x\text{F}_y\text{H}_z$ ,  $[(\text{CH}_2)_m\text{O}]_x(\text{CH}_2\text{CF}_2\text{O})_y(\text{CF}_2\text{CF}_2\text{O})_z(\text{CF}_2)_2\text{CF}_2\text{CH}_2\text{O}(\text{CH}_2)_p\text{OH}$ ,  $\text{CH}_2\text{C}(\text{OH})\text{C}_x\text{F}_y\text{H}_z$ ,  $\text{C}_x\text{F}_y\text{H}_z\text{O}_p$ ,  $\text{COC}_x\text{F}_y\text{H}_z$ ,  $\text{OCH}_2\text{C}_x\text{F}_z[\text{C}_x\text{F}_2\text{O}]_m\text{F}$ ,  $\text{CH}_2\text{C}(\text{CH}_3)\text{CO}_2\text{C}_x\text{H}_z(\text{CF}_2)_m\text{CF}_3$ ,  $\text{CH}_2(\text{CF}_2\text{O})_x(\text{CF}_2\text{CF}_2\text{O})_y(\text{CF}_2\text{O})_z\text{CF}_2\text{CH}_2\text{OH}$ ,  $\text{COCF}(\text{CF}_3)-[\text{CF}(\text{CF}_3)\text{CF}_2\text{O}]_m\text{F}$ ,  $\text{NHC}_x\text{F}_y\text{H}_z\text{O}_p$ ,  $\text{CH}_2\text{CF}_2\text{O}[\text{CF}_2\text{CF}_2\text{O}]_m(\text{CF}_2\text{OCF}_2\text{CH}_2\text{OH})$ ,  $\text{COC}_x\text{H}_z(\text{CF}_2)_m\text{CF}_3$ ,  $\text{COCF}_2\text{O}[\text{CF}_2\text{CF}_2\text{O}]_n\text{CF}_2\text{OCF}_2\text{CO}_2\text{H}$ ,  $[(\text{CH}_2)_m\text{O}]_x(\text{CH}_2\text{CF}_2\text{O})_y(\text{CF}_2\text{CF}_2\text{O})_z\text{CF}_2\text{CH}_2\text{O}(\text{CH}_2)_p\text{OH}$ ,  $\text{N}[\text{C}_x\text{F}_y\text{H}_z]_p$ ,  $\text{C}_x\text{H}_z\text{CO}_2\text{C}_x\text{H}_z(\text{CF}_2)_m\text{CF}_3$ ,  $\text{COC}_x\text{F}_y[\text{C}_p\text{F}_2\text{O}]_m\text{F}$ , and m, x, p, y, z are integers from 1 to 150 inclusive.

11. The fluorinated biopolymer of any of claim 4, wherein X is fluoroalkyl, fluoroaryl, fluoroacyl, perfluoroalkyl, perfluoroaryl, perfluoroacyl, perfluoropolymer, fluoroamine, fluorocarbamate, fluorotriazine, fluorosulfonylalkyl derivatives,  $\text{CF}_2\text{Cl}$ ,  $\text{SO}_2[\text{CF}_2]_x\text{CF}_3$ , F,  $\text{CF}_3$ ,  $\text{COC}_x\text{F}_y$ ,  $\text{C}_x\text{F}_y\text{H}_z$ ,  $([\text{CH}_2]_m\text{O})_x(\text{CH}_2\text{CF}_2\text{O})_y(\text{CF}_2\text{CF}_2\text{O})_z(\text{CF}_2)_2\text{CF}_2\text{CH}_2\text{O}(\text{CH}_2)_p\text{OH}$ ,  $\text{CH}_2\text{C}(\text{OH})\text{C}_x\text{F}_y\text{H}_z$ ,  $\text{C}_x\text{F}_y\text{H}_z\text{O}_p$ ,  $\text{COC}_x\text{F}_y\text{H}_z$ ,  $\text{OCH}_2\text{C}_x\text{F}_z[\text{C}_x\text{F}_z\text{O}]_m\text{F}$ ,  $\text{CH}_2\text{C}(\text{CH}_3)\text{CO}_2\text{C}_x\text{H}_z(\text{CF}_2)_m\text{CF}_3$ ,  $\text{CH}_2(\text{CF}_2\text{O})_x(\text{CF}_2\text{CF}_2\text{O})_y(\text{CF}_2\text{O})_z\text{CF}_2\text{CH}_2\text{OH}$ ,  $\text{COCF}(\text{CF}_3)-[\text{CF}(\text{CF}_3)\text{CF}_2\text{O}]_m\text{F}$ ,  $\text{NHC}_x\text{F}_y\text{H}_z\text{O}_p$ ,  $\text{CH}_2\text{CF}_2\text{O}[\text{CF}_2\text{CF}_2\text{O}]_m(\text{CF}_2\text{OCF}_2\text{CH}_2\text{OH})$ ,  $\text{COC}_x\text{H}_z(\text{CF}_2)_m\text{CF}_3$ ,  $\text{COCF}_2\text{O}[\text{CF}_2\text{CF}_2\text{O}]_n\text{CF}_2\text{OCF}_2\text{CO}_2\text{H}$ ,  $([\text{CH}_2]_m\text{O})_x(\text{CH}_2\text{CF}_2\text{O})_y(\text{CF}_2\text{CF}_2\text{O})_z\text{CF}_2\text{CH}_2\text{O}(\text{CH}_2)_p\text{OH}$ ,  $\text{N}[\text{C}_x\text{F}_y\text{H}_z]_p$ ,  $\text{C}_x\text{H}_z\text{CO}_2\text{C}_x\text{H}_z(\text{CF}_2)_m\text{CF}_3$ ,  $\text{COC}_x\text{F}_y[\text{C}_p\text{F}_z\text{O}]_m\text{F}$ , and m, x, p, y, z are integers from 1 to 150 inclusive.




FIG. 1

**THIS PAGE BLANK (USPTO)**

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
23 October 2003 (23.10.2003)

PCT

(10) International Publication Number  
**WO 2003/087165 A3**

(51) International Patent Classification<sup>7</sup>: **C08B 37/00**,  
C08H 1/00, C08B 31/12, 11/06, 11/12, 11/193, 13/00,  
C08H 1/06, C08G 65/48, C08F 8/18, 216/06, C08G 73/02,  
A61K 49/06, 49/12, 49/14, 49/16

(21) International Application Number:  
PCT/US2003/011039

(22) International Filing Date: 11 April 2003 (11.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/372,500 11 April 2002 (11.04.2002) US

(71) Applicant (for all designated States except US): **CAR-  
BOMER, INC.** [US/US]; 6324 Ferris Square, San Diego,  
CA 92121 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **YALPANI, Manssur**  
[US/US]; 17136 Blue Skies Ridge, Rancho Santa Fe, CA  
92127 (US).

(74) Agents: **SALIWANCHIK, David, R.** et al.; Saliwanchik,  
Lloyd & Saliwanchik, Suite A-1, 2421 N.W. 41st Street,  
Gainesville, FL 32606-6669 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,  
SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,  
UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GI, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— with international search report

(88) Date of publication of the international search report:  
8 January 2004

[Continued on next page]

(54) Title: **BIOCOMPATIBLE MATERIALS AND PROBES**



(57) Abstract: The present invention relates to fluorinated biopolymer and polymer derivatives useful as imaging probes, diagnostic agents and contrast agents and to imaging methods employing the fluorinated biopolymers and polymers.

WO 2003/087165 A3



*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## INTERNATIONAL SEARCH REPORT

Interr      if Application No

PCT/US 03/11039

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7	C08B37/00	C08H1/00	C08B31/12	C08B11/06	C08B11/12
	C08B11/193	C08B13/00	C08H1/06	C08G65/48	C08F8/18
	C08F216/06	C08G73/02	A61K49/06	A61K49/12	A61K49/14

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C08B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 91 12824 A (BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM) 5 September 1991 (1991-09-05) page 2, line 5 - line 32 page 4, line 1 - page 7, line 20 page 10, line 10 - line 26 page 13, line 1 - line 34 claims 1,2,10,12 ---	1-3,6, 8-10
X	WO 94 03210 A (INSTITUTE OF CANCER RESEARCH) 17 February 1994 (1994-02-17) page 13, line 19 - line 24 page 34, line 7 - line 12 abstract; claims --- -/--	4,8,11

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

17 July 2003

Date of mailing of the international search report

16 OCT 2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

MAZET Jean-François

## INTERNATIONAL SEARCH REPORT

Intern Application No

PCT/US 03/11039

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 A61K49/16

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 116 599 A (ROGERS JR ET AL.) 26 May 1992 (1992-05-26) column 2, line 62 - line 68 column 5, line 30 - line 42 column 5, line 64 - line 68 claims 1,3-5 ---	1-11
A	WO 89 03693 A (FLUOROMED PHARMACEUTICAL INC.) 5 May 1989 (1989-05-05) ---	
X	EP 0 563 978 A (AQUALON COMPANY) 6 October 1993 (1993-10-06) claims ---	1
X	US 3 489 504 A (ROBERT D. ENGLERT) 13 January 1970 (1970-01-13) claims -----	1



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&amp;" document member of the same patent family

Date of the actual completion of the international search

17 July 2003

Date of mailing of the international search report

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

MAZET Jean-François



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 03/11039

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
  
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
  
1-6, 8-11 (in part)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

Intern: Application No

PCT/US 03/11039

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9112824	A	05-09-1991	US 5236694 A	17-08-1993
			AT 125712 T	15-08-1995
			AU 641233 B	16-09-1993
			AU 7453991 A	18-09-1991
			CA 2075953 A	22-08-1991
			DE 69111798 D	07-09-1995
			DE 69111798 T	30-11-1995
			EP 0517788 A	16-12-1992
			ES 2075433 T	01-10-1995
			JP 5506432 T	22-09-1993
			US 5397562 A	14-03-1995
			US 5422094 A	06-06-1995
WO 9403210	A	17-02-1994	NONE	
US 5116599	A	26-05-1992	AT 136223 T	15-04-1996
			AU 651559 B	28-07-1994
			AU 6164590 A	11-03-1991
			CA 2064567 A	01-02-1991
			DE 69026384 D	09-05-1996
			DE 69026384 T	08-08-1996
			DK 485479 T	13-05-1996
			EP 0485479 A	20-05-1992
			ES 2087161 T	16-07-1996
			JP 5501869 T	08-04-1993
			US 5324504 A	28-06-1994
			WO 9101759 A	21-02-1991
			US 5397563 A	14-03-1995
			US 5234680 A	10-08-1993
WO 8903693	A	05-05-1989	AU 2803289 A	23-05-1989
EP 563978	A	06-10-1993	US 5290829 A	01-03-1994
			AT 170193 T	15-09-1998
			CA 2093205 A	03-10-1993
			DE 69320515 D	01-10-1998
			DE 69320515 T	07-01-1999
			DK 563978 T	25-05-1999
			ES 2121580 T	01-12-1998
			GR 3027741 T	30-11-1998
US 3489504	A	13-01-1970	NONE	

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**